<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>OLANZAPINE- olanzapineÂ injection, powder, for solutionÂ </strong><br>TYA Pharmaceuticals<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Olanzapine for Injection safely and effectively.  See full prescribing information for Olanzapine for Injection. Olanzapine for Injection, Powder, For Solution for  Intramuscular use Initial U.S. Approval: 1996
        <br><br>
</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning</span></h1>
<ul><li><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Olanzapine for Injection is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. (5.1, 5.14, 17.2)</span></li></ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">None </p></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning</span></h1>
<ul><li><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Olanzapine for Injection is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. (5.1, 5.14, 17.2)</span></li></ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Olanzapine for Injection is an atypical antipsychotic indicated:  (<a href="#section-1">1</a>)</p>
<ul>
<li>Treatment of acute <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> associated with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar I <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>. (1.4)</li>
<li>Efficacy was established in three 1-day trials in adults. (14.3)</li>
</ul>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<a name="id_720527d6-1e06-47dd-a8e1-cb76a926e175"></a><table border="single">
<col width="50.1%">
<col width="50.1%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span> associated with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> and Bipolar I <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> in adults (2.4)  (<a href="#section-2">2</a>)</p></td>
<td class="Botrule Rrule" align="left" valign="top">IM: 10 mg (5 mg or 7.5 mg when clinically warranted) Assess for <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> prior to subsequent dosing (max. 3 doses 2 to 4 hrs apart)
                                                <br>
</td>
</tr></tbody>
</table>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>Intramuscular Injection: 10 mg vial (3)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>None with Olanzapine monotherapy.</li>
<li>When using Olanzapine in combination with lithium or valproate, refer to the Contraindications section of the package inserts for those products. (4)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and increased incidence of cerebrovascular adverse events (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack). (5.1)
                                        <span class="Italics">Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span>:</span>
</li>
<li>The possibility of a <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span> is inherent in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and in bipolarÂ I disorder, and close supervision of high-risk patients should accompany drug therapy.(5.2)
                                        <span class="Italics"><span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span>:</span>
</li>
<li>Manage with immediate discontinuation and close monitoring. (5.3)
                                        <span class="Italics"><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span>:</span>
</li>
<li>In some cases extreme and associated with <span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span> or hyperosmolar <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, has been reported in patients taking olanzapine. Patients taking olanzapine should be monitored for symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and undergo fasting blood glucose testing at the beginning of, and periodically during, treatment. (5.4)
                                        <span class="Italics"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>:</span>
</li>
<li>Undesirable alterations in lipids have been observed. Appropriate clinical monitoring is recommended, including fasting blood lipid testing at the beginning of, and periodically during, treatment. (5.5)
                                        <span class="Italics"><span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span>:</span>
</li>
<li>Potential consequences of <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> should be considered. Patients should receive regular monitoring of weight. (5.6)
                                        <span class="Italics"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span>:</span>
</li>
<li>Discontinue if clinically appropriate. (5.7)
                                        <span class="Italics"><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span>:</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span> associated with <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and, in some patients, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, may occur especially during initial dose titration. Use caution in patients with cardiovascular disease, cerebrovascular disease, and those conditions that could affect hemodynamic responses. (5.8)
                                        <span class="Italics"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>:</span>
</li>
<li>Has been reported with antipsychotics, including Olanzapine for Injection. Patients with a history of a clinically significant low white blood cell count (WBC) or drug induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of Olanzapine for Injection should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors. (5.9)
                                        <span class="Italics"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>:</span>
</li>
<li>Use cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or with conditions that potentially lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold. (5.11)
                                        <span class="Italics"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>:</span>
</li>
<li>Has potential to impair judgment, thinking, and motor skills. Use caution when operating machinery. (5.12)
                                        <span class="Italics">Potential for Cognitive and Motor Impairment:</span>
</li>
<li>May elevate prolactin levels. (5.15)
                                        <span class="Italics"><span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span>:</span>
</li>
<li>. (5.16)
                                        <span class="Italics">Use in Combination with, Lithium or Valproate</span>
</li>
<li>Monitor fasting blood glucose and lipid profiles at the beginning of, and periodically during, treatment. (5.17)
                                        <span class="Italics">Laboratory Tests:</span>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Most common adverse reactions (â‰¥5% and at least twice that for placebo) associated with:</span> </p>
<p class="Highlighta"><span class="Italics">Oral Olanzapine Monotherapy:</span> </p>
<ul>
<li>- <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">personality disorder</span>, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (6.1)
                                        <span class="Underline"><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> (Adults)</span>
</li>
<li>- sedation, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> (6.1)
                                        <span class="Underline"><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> (Adolescents)</span>
</li>
<li>â€“ <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> (6.1)
                                        <span class="Underline"><span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> or Mixed Episodes, <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> (Adults)</span>
</li>
<li>â€“ sedation, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span> (6.1)
                                        <span class="Underline"><span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> or Mixed Episodes, <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> (Adolescents)</span>
</li>
</ul>
<p class="Highlighta"><span class="Italics">Combination of Olanzapine  and Lithium or Valproate:</span> </p>
<ul><li>â€“ <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, speech disorder, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">increased salivation</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> (6.1)
                                        <span class="Underline"><span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> or Mixed Episodes, <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> (Adults)</span>
</li></ul>
<p class="Highlighta"><span class="Italics">Olanzapine for Injection:</span> </p>
<ul><li>â€“ <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (6.1)
                                        <span class="Underline"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span> with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> and Bipolar I <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> (Adults)</span>
</li></ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at or FDA at 1-800-FDA-1088 or
                                        <span class="Bold">1-800-525-8747</span><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>May potentiate <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>. (7.1, 7.2)
                                        <span class="Italics">Diazepam:</span>
</li>
<li>May potentiate <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>. (7.1)
                                        <span class="Italics">Alcohol:</span>
</li>
<li>Increased clearance of olanzapine. (7.1)
                                        <span class="Italics">Carbamazepine:</span>
</li>
<li>May increase olanzapine levels. (7.1)
                                        <span class="Italics">Fluvoxamine:</span>
</li>
<li>Caution should be used when taken in combination with other centrally acting drugs and alcohol. (7.2)
                                        <span class="Italics">CNS Acting Drugs:</span>
</li>
<li>Enhanced antihypertensive effect. (7.2)
                                        <span class="Italics">Antihypertensive Agents:</span>
</li>
<li>May antagonize levodopa/dopamine agonists. (7.2)
                                        <span class="Italics">Levodopa and Dopamine Agonists:</span>
</li>
<li>Increased <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> with IM olanzapine. (7.2)
                                        <span class="Italics">Lorazepam (IM):</span>
</li>
<li>When using olanzapine in combination with lithium or valproate, refer to the Drug Interactions sections of the package insert for those products. (7.2)
                                        <span class="Italics">Other Concomitant Drug Therapy:</span>
</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Olanzapine for Injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. (8.1)
                                        <span class="Italics">Pregnancy:</span>
</li>
<li>Breast-feeding is not recommended. (8.3)
                                        <span class="Italics">Nursing Mothers:</span>
</li>
<li>Safety and effectiveness of Olanzapine for Injection in children &lt;18 years of age have not been established. (8.4)
                                        <span class="Italics">Pediatric Use:</span>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 9/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.4 Olanzapine for Injection <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span> Associated with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> and BipolarÂ I <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.4 Olanzapine for Injection: <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span> Associated with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> and Bipolar I <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10 <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Potential for Cognitive and Motor Impairment</a></h2>
<h2><a href="#section-5.13" class="toc">5.13 Body Temperature Regulation</a></h2>
<h2><a href="#section-5.14" class="toc">5.14 Use in Patients with Concomitant Illness</a></h2>
<h2><a href="#section-5.15" class="toc">5.15 <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span></a></h2>
<h2><a href="#section-5.16" class="toc">5.16 Use in Combination with Lithium, or Valproate</a></h2>
<h2><a href="#section-5.17" class="toc">5.17 Laboratory Tests</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Vital Signs and Laboratory Studies</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Potential for Other Drugs to Affect Olanzapine</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Potential for Olanzapine to Affect Other Drugs</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-10.1" class="toc">10.1 Human Experience</a></h2>
<h2><a href="#section-10.2" class="toc">10.2 Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></a></h2>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-13.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.3 <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span> Associated with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> and Bipolar I <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></a></h2>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-15.2" class="toc">16.2 Storage and Handling</a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.2 Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span>: Increased Mortality and Cerebrovascular Adverse Events (CVAE), Including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></a></h2>
<h2><a href="#section-16.2" class="toc">17.3 <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)</a></h2>
<h2><a href="#section-16.3" class="toc">17.4 <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></a></h2>
<h2><a href="#section-16.4" class="toc">17.5 <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></a></h2>
<h2><a href="#section-16.5" class="toc">17.6 <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></a></h2>
<h2><a href="#section-16.6" class="toc">17.7 <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></a></h2>
<h2><a href="#section-16.7" class="toc">17.8 Potential for Cognitive and Motor Impairment</a></h2>
<h2><a href="#section-16.8" class="toc">17.9 Body Temperature Regulation</a></h2>
<h2><a href="#section-16.9" class="toc">17.10 Concomitant Medication</a></h2>
<h2><a href="#section-16.10" class="toc">17.11 Alcohol</a></h2>
<h2><a href="#section-16.11" class="toc">17.13 Use in Specific Populations</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_ef295384-6c3c-4fc9-97f4-06e3721b6eb3"></a><a name="section-1"></a><p></p>
<h1>WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></h1>
<p class="First"><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in drug-treated patients of between 1.6 to 1.7 times the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were varied, most of the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> appeared to be either cardiovascular (e.g., <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>) or infectious (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Olanzapine for Injection is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> WARNINGS AND PRECAUTIONS ( , ) AND  PATIENT COUNSELING INFORMATION ( ) .
                                <span class="Italics">[see</span><a href="#i4i_section_id_617516a7-e25b-4b1e-8645-61d3c78a63d5">5.1</a><a href="#i4i_section_id_576e9dbd-8b0e-41d7-a537-3f97b646d71f">5.14</a><a href="#i4i_section_id_b438b5c0-6445-4cb2-90b5-734f1d3194ac">17.2</a><span class="Italics">]</span></span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_2cd3e3f4-1801-43d7-9c14-a30f5af82b61"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c934c9a5-a551-4503-b166-1f668791a480"></a><a name="section-1.1"></a><p></p>
<h2>1.4 Olanzapine for Injection <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span> Associated with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> and BipolarÂ I <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></h2>
<p class="First">Olanzapine for InjectionÂ  is indicated for the treatment of acute <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> associated with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar I <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>.</p>
<p>Efficacy was demonstrated in 3 short-term (24 hours of IM treatment) placebo-controlled trials in <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> adult inpatients with: <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes)
                                    <span class="Italics">[see Â </span><span class="Bold">CLINICAL STUDIES ( )
                                        <a href="#i4i_section_id_d44b2269-6f37-4812-be3e-8301e967a954">14.3</a></span><span class="Italics">].</span></p>
<p>â€œPsychomotor agitationâ€? is defined in DSM-IV as â€œexcessive motor activity associated with a feeling of inner <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>.â€? Patients experiencing <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self-exhausting behavior, leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_3cf5f9c6-270f-42d9-ba13-7b3f9a5607dc"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f7e3ec04-6f61-4909-89d3-21577d8fac15"></a><a name="section-2.1"></a><p></p>
<h2>2.4 Olanzapine for Injection: <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span> Associated with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> and Bipolar I <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></h2>
<p class="First"><span class="Bold"><span class="Italics">Dose Selection for <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitated</span> Adult Patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> and Bipolar I <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></span></span></p>
<p>The efficacy of intramuscular olanzapine for injection in controlling <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> in these disorders was demonstrated in a dose range of 2.5 mg to 10 mg. The recommended dose in these patients is 10 mg. A lower dose of 5 or 7.5 mg may be considered when clinical factors warrant . If <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> warranting additional intramuscular doses persists following the initial dose, subsequent doses up to 10 mg may be given. However, the efficacy of repeated doses of intramuscular olanzapine for injection in <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> patients has not been systematically evaluated in controlled clinical trials. Also, the safety of total daily doses greater than 30 mg, or 10 mg injections given more frequently than 2 hours after the initial dose, and 4 hours after the second dose have not been evaluated in clinical trials. Maximal dosing of intramuscular olanzapine (e.g., 3 doses of 10 mg administered 2 to 4 hours apart) may be associated with a substantial occurrence of significant <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> Thus, it is recommended that patients requiring subsequent intramuscular injections be assessed for <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> prior to the administration of any subsequent doses of intramuscular olanzapine for injection. The administration of an additional dose to a patient with a clinically significant postural change in systolic blood pressure is not recommended.
                                    <span class="Italics">[see Â </span><span class="Bold">CLINICAL STUDIES ( )
                                        <a href="#i4i_section_id_d44b2269-6f37-4812-be3e-8301e967a954">14.3</a></span><span class="Italics">]</span><span class="Italics">[see Â </span><span class="Bold">WARNINGS AND PRECAUTIONS ( )
                                        <a href="#i4i_section_id_21fd3f46-acca-42c1-b2b9-21545674f9f4">5.8</a></span><span class="Italics">].</span></p>
<p>If ongoing olanzapine therapy is clinically indicated, oral olanzapine may be initiated in a range of 5 to 20 mg/day as soon as clinically appropriate
                                    <span class="Italics">.</span></p>
<p><span class="Bold"><span class="Italics">Intramuscular Dosing in Special Populations</span></span></p>
<p>A dose of 5 mg/injection should be considered for geriatric patients or when other clinical factors warrant. A lower dose of 2.5 mg/injection should be considered for patients who otherwise might be debilitated, be predisposed to hypotensive reactions, or be more pharmacodynamically sensitive to olanzapine AND .
                                    <span class="Italics">[see Â </span><span class="Bold">WARNINGS AND PRECAUTIONS ( ), DRUG INTERACTIONS ( ),
                                        <a href="#i4i_section_id_576e9dbd-8b0e-41d7-a537-3f97b646d71f">5.14</a><a href="#i4i_interactions_id_59a2af3d-f786-459e-84d4-02bc8ff712f1">7</a></span><span class="Bold">CLINICAL PHARMACOLOGY ( )
                                        <a href="#i4i_pharmacokinetics_id_b00c26eb-c1dd-4dc2-912e-49ce4c3d3ecd">12.3</a></span><span class="Italics">]</span></p>
<p><span class="Bold"><span class="Italics">Administration of Olanzapine for Injection</span></span></p>
<p>Olanzapine for InjectionÂ  is intended for intramuscular use only. Do not administer intravenously or subcutaneously. Inject slowly, deep into the <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle mass</span>.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
<p><span class="Bold"><span class="Italics">Directions for Preparation of Olanzapine for Injection with Sterile Water for Injection</span></span></p>
<p>Dissolve the contents of the vial using 2.1 mL of Sterile Water for Injection to provide a solution containing approximately 5 mg/mL of olanzapine. The resulting solution should appear clear and yellow. Olanzapine for Injection reconstituted with Sterile Water for Injection should be used immediately (within 1 hour) after reconstitution.
                                    <span class="Italics">Discard any unused portion.</span></p>
<p>The following table provides injection volumes for delivering various doses of intramuscular olanzapine for injection reconstituted with Sterile Water for Injection.</p>
<a name="id_5c1c586a-0934-4061-a2c4-604f542bc8a0"></a><table border="none" width="441">
<col width="52.2%">
<col width="47.8%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="center" valign="middle">Dose, mg Olanzapine</td>
<td align="center" valign="middle">Volume of Injection, mL</td>
</tr>
<tr>
<td align="center" valign="middle">10</td>
<td align="center" valign="middle">Withdraw total contents of vial</td>
</tr>
<tr>
<td align="center" valign="middle">7.5</td>
<td align="center" valign="middle">1.5</td>
</tr>
<tr>
<td align="center" valign="middle">5</td>
<td align="center" valign="middle">1</td>
</tr>
<tr class="Botrule Last">
<td align="center" valign="middle">2.5</td>
<td align="center" valign="middle">0.5</td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Italics">Physical Incompatibility Information</span></span></p>
<p>Olanzapine for Injection should be reconstituted only with Sterile Water for Injection. Olanzapine for Injection should not be combined in a syringe with diazepam injection because precipitation occurs when these products are mixed. Lorazepam injection should not be used to reconstitute Olanzapine for Injection as this combination results in a delayed reconstitution time. Olanzapine for Injection should not be combined in a syringe with haloperidol injection because the resulting low pH has been shown to degrade olanzapine over time.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_a14ab0b1-69f1-47fd-8e9b-acdd7dd715d5"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Olanzapine for Injection is available in 10 mg vial (1s).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_0bf36eb8-2e64-428b-bfef-03b3cff0e34a"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<ul>
<li>None with Olanzapine for Injection monotherapy.</li>
<li>For specific information about the contraindications of lithium or valproate, refer to the Contraindications section of the package inserts for these other products.</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_6042a0c1-04b0-4c54-9216-943b8a69d0b3"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_617516a7-e25b-4b1e-8645-61d3c78a63d5"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span></h2>
<p class="First"><span class="Bold"><span class="Italics">Increased Mortality</span></span></p>
<p>AND .
                                    <span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Olanzapine for Injection is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span></span><span class="Italics">[seeÂ </span><span class="Bold">BOXED WARNING, WARNINGS AND PRECAUTIONS ( )
                                        <a href="#i4i_section_id_576e9dbd-8b0e-41d7-a537-3f97b646d71f">5.14</a></span><span class="Bold">PATIENT COUNSELING INFORMATION ( )
                                        <a href="#i4i_section_id_b438b5c0-6445-4cb2-90b5-734f1d3194ac">17.2</a></span><span class="Italics">]</span><br></p>
<p>In placebo-controlled clinical trials of elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, the incidence of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in olanzapine-treated patients was significantly greater than placebo-treated patients (3.5% vs 1.5%, respectively).</p>
<p><span class="Bold"><span class="Italics">Cerebrovascular Adverse Events (CVAE), Including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></span></span></p>
<p>Cerebrovascular adverse events (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack), including fatalities, were reported in patients in trials of olanzapine in elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. In placebo-controlled trials, there was a significantly higher incidence of cerebrovascular adverse events in patients treated with olanzapine compared to patients treated with placebo. Olanzapine is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> .
                                    <span class="Italics">[seeÂ </span><span class="Bold">BOXED WARNING AND PATIENT COUNSELING INFORMATION ( )
                                        <a href="#i4i_section_id_b438b5c0-6445-4cb2-90b5-734f1d3194ac">17.2</a></span><span class="Italics">]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a7658327-a5af-4f8c-bbc3-a2cfd3330c12"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span></h2>
<p class="First">The possibility of a <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span> is inherent in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and in <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span>, and close supervision of high-risk patients should accompany drug therapy. Prescriptions for olanzapine should be written for the smallest quantity consistent with good patient management, in order to reduce the risk of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_910a9ebd-e38e-41e3-bfb9-99663ed38e3b"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)</h2>
<p class="First">A potentially fatal symptom complex sometimes referred to as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) has been reported in association with administration of antipsychotic drugs, including olanzapine. Clinical manifestations of NMS are <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span> and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span> (<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>), and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.</p>
<p>The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to exclude cases where the clinical presentation includes both serious medical illness (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, and primary central nervous system pathology.</p>
<p>The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for NMS.</p>
<p>If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported .
                                    <span class="Italics">[see Â </span><span class="Bold">PATIENT COUNSELING INFORMATION ( )
                                        <a href="#i4i_section_id_29001e4c-fa95-4668-825b-73aaed7888c8">17.3</a></span><span class="Italics">]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5fc99f10-df4d-4ed4-870e-dfe1f1a64919"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></h2>
<p class="First">Physicians should consider the risks and benefits when prescribing olanzapine to patients with an established diagnosis of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, or having borderline increased blood glucose level (fasting 100 to 126 mg/dL, nonfasting 140 to 200 mg/dL). Patients taking olanzapine should be monitored regularly for worsening of glucose control. Patients starting treatment with olanzapine should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> including <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="438872" conceptname="Excessive eating - polyphagia">polyphagia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Patients who develop symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug .
                                    <span class="Italics">[see Â </span><span class="Bold">PATIENT COUNSELING INFORMATION ( )
                                        <a href="#i4i_section_id_67eab0e9-3f5e-48ac-ab86-2a94b1872e60">17.4</a></span><span class="Italics">]</span></p>
<p><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, in some cases extreme and associated with <span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span> or hyperosmolar <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, has been reported in patients treated with atypical antipsychotics including olanzapine. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and the increasing incidence of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in the general population. Epidemiological studies suggest an increased risk of treatment-emergent <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse reactions in patients treated with the atypical antipsychotics. While relative risk estimates are inconsistent, the association between atypical antipsychotics and increases in glucose levels appears to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> on a continuum and olanzapine appears to have a greater association than some other atypical antipsychotics.</p>
<p>Mean increases in blood glucose have been observed in patients treated (median exposure of 9.2 months) with olanzapine in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). The mean increase of serum glucose (fasting and nonfasting samples) from baseline to the average of the 2 highest serum concentrations was 15 mg/dL.</p>
<p>In a study of healthy volunteers, subjects who received olanzapine (N=22) for 3 weeks had a mean increase compared to baseline in fasting blood glucose of 2.3 mg/dL. Placebo-treated subjects (N=19) had a mean increase in fasting blood glucose compared to baseline of 0.34 mg/dL.</p>
<p><span class="Bold"><span class="Italics">Olanzapine Monotherapy in Adults</span></span></p>
<p>In an analysis of 5 placebo-controlled adult olanzapine monotherapy studies with a median treatment duration of approximately 3 weeks, olanzapine was associated with a greater mean change in fasting glucose levels compared to placebo (2.76 mg/dL versus 0.17 mg/dL). The difference in mean changes between olanzapine and placebo was greater in patients with evidence of glucose dysregulation at baseline (patients diagnosed with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or related adverse reactions, patients treated with anti-diabetic agents, patients with a baseline random glucose level â‰¥200 mg/dL, and/or a baseline fasting glucose level â‰¥126 mg/dL). Olanzapine-treated patients had a greater mean HbA1c increase from baseline of 0.04% (median exposure 21 days), compared to a mean HbA1c decrease of 0.06% in placebo-treated subjects (median exposure 17 days).</p>
<p>In an analysis of 8 placebo-controlled studies (median treatment exposure 4 to 5 weeks), 6.1% of olanzapine-treated subjects (N=855) had treatment-emergent <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span> compared to 2.8% of placebo-treated subjects (N=599). shows short-term and long-term changes in fasting glucose levels from adult olanzapine monotherapy studies.
                                    <span class="Bold">Table 2</span></p>
<p><span class="Bold">Table 2: Changes in Fasting Glucose Levels</span><span class="Bold">from Adult Olanzapine Monotherapy Studies</span></p>
<a name="id_8b2d9035-95e3-40ab-81fa-137e22db1b2c"></a><table border="single" width="449">
<col width="14.7%">
<col width="20.6%">
<col width="18.0%">
<col width="8.0%">
<col width="14.0%">
<col width="10.0%">
<col width="14.7%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="3" valign="top"></td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">Up to 12 weeks exposure</span></td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">At least 48 weeks exposure</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Laboratory Analyte</span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Category Change (at least once) from Baseline
                                                    <br></span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Treatment Arm</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">N</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">Patients</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">N</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">Patients</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="4" valign="middle">Fasting Glucose
                                                <br>
</td>
<td class="Botrule Rrule" align="left" rowspan="2" valign="top">Normal to High (&lt;100 mg/dL to â‰¥126 mg/dL)
                                                <br>
</td>
<td class="Botrule Rrule" align="left" valign="top">Olanzapine</td>
<td class="Botrule Rrule" align="center" valign="top">543</td>
<td class="Botrule Rrule" align="center" valign="top">2.2%</td>
<td class="Botrule Rrule" align="center" valign="top">345</td>
<td class="Botrule Rrule" align="center" valign="top">12.8%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="top">293</td>
<td class="Botrule Rrule" align="center" valign="top">3.4%</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Borderline to High (â‰¥100 mg/dL and &lt;126 mg/dL to â‰¥126 mg/dL)
                                                <br>
</td>
<td class="Botrule Rrule" align="left" valign="top">Olanzapine</td>
<td class="Botrule Rrule" align="center" valign="top">178</td>
<td class="Botrule Rrule" align="center" valign="top">17.4%</td>
<td class="Botrule Rrule" align="center" valign="top">127</td>
<td class="Botrule Rrule" align="center" valign="top">26%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Rrule" align="center" valign="top">96</td>
<td class="Rrule" align="center" valign="top">11.5%</td>
<td class="Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
</tr>
</tbody>
</table>
<p>Not Applicable.
                                    <span class="Sup">a</span></p>
<p>The mean change in fasting glucose for patients exposed at least 48 weeks was 4.2 mg/dL (N=487). In analyses of patients who completed 9 to 12 months of olanzapine therapy, mean change in fasting and nonfasting glucose levels continued to increase over time.</p>
<p><span class="Bold"><span class="Italics">Olanzapine Monotherapy in Adolescents</span></span></p>
<p>The safety and efficacy of olanzapine for injection have not been established in patients under the age of 18 years. In an analysis of 3 placebo-controlled olanzapine monotherapy studies of adolescent patients, including those with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> (6 weeks) or <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes) (3 weeks), olanzapine was associated with a greater mean change from baseline in fasting glucose levels compared to placebo (2.68 mg/dL versus -2.59 mg/dL). The mean change in fasting glucose for adolescents exposed at least 24 weeks was 3.1 mg/dL (N=121). shows short-term and long-term changes in fasting blood glucose from adolescent olanzapine monotherapy studies.
                                    <span class="Bold">Table 3</span></p>
<p><span class="Bold">Table 3: Changes in Fasting Glucose Levels from</span><span class="Bold">Adolescent Olanzapine Monotherapy Studies</span></p>
<a name="id_d752cc78-3ac3-4bf4-b70b-b8ad851ae158"></a><table border="single" width="449">
<col width="14.7%">
<col width="20.6%">
<col width="18.0%">
<col width="8.0%">
<col width="14.0%">
<col width="10.0%">
<col width="14.7%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top"></td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">Up to 12 weeks exposure</span></td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">At least 24 weeks exposure</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Laboratory Analyte</span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Category Change (at least once) from Baseline
                                                    <br></span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Treatment Arm</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">N</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Patients</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">N</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Patients</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="4" valign="middle">Fasting Glucose
                                                <br>
</td>
<td class="Botrule Rrule" align="left" rowspan="2" valign="top">Normal to High (&lt;100 mg/dL to â‰¥126 mg/dL)
                                                <br>
</td>
<td class="Botrule Rrule" align="left" valign="top">Olanzapine</td>
<td class="Botrule Rrule" align="center" valign="top">124</td>
<td class="Botrule Rrule" align="center" valign="top">0%</td>
<td class="Botrule Rrule" align="center" valign="top">108</td>
<td class="Botrule Rrule" align="center" valign="top">0.9%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="top">53</td>
<td class="Botrule Rrule" align="center" valign="top">1.9%</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Borderline to High (â‰¥100 mg/dL and &lt;126 mg/dL to â‰¥126 mg/dL)
                                                <br>
</td>
<td class="Botrule Rrule" align="left" valign="top">Olanzapine</td>
<td class="Botrule Rrule" align="center" valign="top">14</td>
<td class="Botrule Rrule" align="center" valign="top">14.3%</td>
<td class="Botrule Rrule" align="center" valign="top">13</td>
<td class="Botrule Rrule" align="center" valign="top">23.1%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Rrule" align="center" valign="top">13</td>
<td class="Rrule" align="center" valign="top">0%</td>
<td class="Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
</tr>
</tbody>
</table>
<p>Not Applicable.
                                    <span class="Sup">a</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_124564fe-51e9-46ca-a1ce-7dc43aa9fb93"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></h2>
<p class="First">Undesirable alterations in lipids have been observed with olanzapine use. Clinical monitoring, including baseline and periodic follow-up lipid evaluations in patients using olanzapine, is recommended .
                                    <span class="Italics">[see Â </span><span class="Bold">PATIENT COUNSELING INFORMATION ( )
                                        <a href="#i4i_section_id_8e84e0b7-f47c-4c8d-8501-55752474fbed">17.5</a></span><span class="Italics">]</span></p>
<p>Clinically significant, and sometimes very high (&gt;500 mg/dL), elevations in triglyceride levels have been observed with olanzapine use. Modest mean increases in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> have also been seen with olanzapine use.</p>
<p><span class="Bold"><span class="Italics">Olanzapine Monotherapy in Adults</span></span></p>
<p>In an analysis of 5 placebo-controlled olanzapine monotherapy studies with treatment duration up to 12 weeks, olanzapine-treated patients had increases from baseline in mean fasting total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, and triglycerides of 5.3 mg/dL, 3 mg/dL, and 20.8 mg/dL respectively compared to decreases from baseline in mean fasting total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, and triglycerides of 6.1 mg/dL, 4.3 mg/dL, and 10.7 mg/dL for placebo-treated patients. For fasting HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, no clinically meaningful differences were observed between olanzapine-treated patients and placebo-treated patients. Mean increases in fasting lipid values (total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, and triglycerides) were greater in patients without evidence of lipid dysregulation at baseline, where lipid dysregulation was defined as patients diagnosed with <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span> or related adverse reactions, patients treated with lipid lowering agents, or patients with high baseline lipid levels.</p>
<p>In long-term studies (at least 48 weeks), patients had increases from baseline in mean fasting total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, and triglycerides of 5.6 mg/dL, 2.5 mg/dL, and 18.7 mg/dL, respectively, and a mean decrease in fasting HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> of 0.16 mg/dL. In an analysis of patients who completed 12 months of therapy, the mean nonfasting total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> did not increase further after approximately 4 to 6 months.</p>
<p>The proportion of patients who had changes (at least once) in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> or triglycerides from normal or borderline to high, or changes in HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> from normal or borderline to low, was greater in long-term studies (at least 48 weeks) as compared with short-term studies. shows categorical changes in fasting lipids values.
                                    <span class="Bold">Table 4</span></p>
<p><span class="Bold">Table 4: Changes in Fasting Lipids Values from Adult</span><span class="Bold">Olanzapine Monotherapy Studies</span></p>
<a name="id_ca6ff8c1-f716-465c-aa2c-49e861e28b42"></a><table border="single" width="461">
<col width="13.9%">
<col width="24.2%">
<col width="17.4%">
<col width="11.5%">
<col width="11.6%">
<col width="9.6%">
<col width="11.6%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="3" valign="top"></td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">Up to 12 weeks exposure</span></td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">At least 48 weeks exposure</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Laboratory Analyte</span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Category Change (at least once) from Baseline
                                                    <br></span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Treatment Arm</span></td>
<td class="Botrule Rrule" align="center" valign="top">
<br><span class="Bold">N</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br><span class="Bold">Patients</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br><span class="Bold">N</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br><span class="Bold">Patients</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="6" valign="middle">Fasting Triglycerides
                                                <br>
</td>
<td class="Botrule Rrule" align="left" rowspan="2" valign="top">Increase by â‰¥50 mg/dL</td>
<td class="Botrule Rrule" align="left" valign="top">Olanzapine</td>
<td class="Botrule Rrule" align="center" valign="top">745</td>
<td class="Botrule Rrule" align="center" valign="top">39.6%</td>
<td class="Botrule Rrule" align="center" valign="top">487</td>
<td class="Botrule Rrule" align="center" valign="top">61.4%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="top">402</td>
<td class="Botrule Rrule" align="center" valign="top">26.1%</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Normal to High (&lt;150 mg/dL to â‰¥200 mg/dL)
                                                <br>
</td>
<td class="Botrule Rrule" align="left" valign="top">Olanzapine</td>
<td class="Botrule Rrule" align="center" valign="top">457</td>
<td class="Botrule Rrule" align="center" valign="top">9.2%</td>
<td class="Botrule Rrule" align="center" valign="top">293</td>
<td class="Botrule Rrule" align="center" valign="top">32.4%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="top">251</td>
<td class="Botrule Rrule" align="center" valign="top">4.4%</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">NA
                                                    <span class="Sup">a</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Borderline to High (â‰¥150 mg/dL and &lt;200 mg/dL to â‰¥200 mg/dL)
                                                <br>
</td>
<td class="Botrule Rrule" align="left" valign="top">Olanzapine</td>
<td class="Botrule Rrule" align="center" valign="top">135</td>
<td class="Botrule Rrule" align="center" valign="top">39.3%</td>
<td class="Botrule Rrule" align="center" valign="top">75</td>
<td class="Botrule Rrule" align="center" valign="top">70.7%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="top">65</td>
<td class="Botrule Rrule" align="center" valign="top">20%</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="7" valign="top"></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="6" valign="middle">Fasting Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span>
                                                <br>
</td>
<td class="Botrule Rrule" align="left" rowspan="2" valign="top">Increase by â‰¥40 mg/dL</td>
<td class="Botrule Rrule" align="left" valign="top">Olanzapine</td>
<td class="Botrule Rrule" align="center" valign="top">745</td>
<td class="Botrule Rrule" align="center" valign="top">21.6%</td>
<td class="Botrule Rrule" align="center" valign="top">489</td>
<td class="Botrule Rrule" align="center" valign="top">32.9%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="top">402</td>
<td class="Botrule Rrule" align="center" valign="top">9.5%</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Normal to High (&lt;200 mg/dL to â‰¥240 mg/dL)
                                                <br>
</td>
<td class="Botrule Rrule" align="left" valign="top">Olanzapine</td>
<td class="Botrule Rrule" align="center" valign="top">392</td>
<td class="Botrule Rrule" align="center" valign="top">2.8%</td>
<td class="Botrule Rrule" align="center" valign="top">283</td>
<td class="Botrule Rrule" align="center" valign="top">14.8%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="top">207</td>
<td class="Botrule Rrule" align="center" valign="top">2.4%</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Borderline to High (â‰¥200 mg/dL and &lt;240 mg/dL to â‰¥240 mg/dL)
                                                <br>
</td>
<td class="Botrule Rrule" align="left" valign="top">Olanzapine</td>
<td class="Botrule Rrule" align="center" valign="top">222</td>
<td class="Botrule Rrule" align="center" valign="top">23%</td>
<td class="Botrule Rrule" align="center" valign="top">125</td>
<td class="Botrule Rrule" align="center" valign="top">55.2%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="top">112</td>
<td class="Botrule Rrule" align="center" valign="top">12.5%</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="7" valign="top"></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="6" valign="middle">Fasting LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span>
                                                <br>
</td>
<td class="Botrule Rrule" align="left" rowspan="2" valign="top">Increase by â‰¥30 mg/dL</td>
<td class="Botrule Rrule" align="left" valign="top">Olanzapine</td>
<td class="Botrule Rrule" align="center" valign="top">536</td>
<td class="Botrule Rrule" align="center" valign="top">23.7%</td>
<td class="Botrule Rrule" align="center" valign="top">483</td>
<td class="Botrule Rrule" align="center" valign="top">39.8%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="top">304</td>
<td class="Botrule Rrule" align="center" valign="top">14.1%</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Normal to High (&lt;100 mg/dL to â‰¥160 mg/dL)
                                                <br>
</td>
<td class="Botrule Rrule" align="left" valign="top">Olanzapine</td>
<td class="Botrule Rrule" align="center" valign="top">154</td>
<td class="Botrule Rrule" align="center" valign="top">0%</td>
<td class="Botrule Rrule" align="center" valign="top">123</td>
<td class="Botrule Rrule" align="center" valign="top">7.3%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="top">82</td>
<td class="Botrule Rrule" align="center" valign="top">1.2%</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Borderline to High (â‰¥100 mg/dL and &lt;160 mg/dL to â‰¥160 mg/dL)
                                                <br>
</td>
<td class="Botrule Rrule" align="left" valign="top">Olanzapine</td>
<td class="Botrule Rrule" align="center" valign="top">302</td>
<td class="Botrule Rrule" align="center" valign="top">10.6%</td>
<td class="Botrule Rrule" align="center" valign="top">284</td>
<td class="Botrule Rrule" align="center" valign="top">31%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Rrule" align="center" valign="top">173</td>
<td class="Rrule" align="center" valign="top">8.1%</td>
<td class="Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
</tr>
</tbody>
</table>
<p>Not Applicable.
                                    <span class="Sup">a</span></p>
<p>In phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), over a median exposure of 9.2 months, the mean increase in triglycerides in patients taking olanzapine was 40.5 mg/dL. In phase 1 of CATIE, the mean increase in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> was 9.4 mg/dL.</p>
<p><span class="Bold"><span class="Italics">Olanzapine Monotherapy in Adolescents</span></span></p>
<p>The safety and efficacy of olanzapine for injection have not been established in patients under the age of 18 years. In an analysis of 3 placebo-controlled olanzapine monotherapy studies of adolescents, including those with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> (6 weeks) or <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes) (3 weeks), olanzapine-treated adolescents had increases from baseline in mean fasting total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, and triglycerides of 12.9 mg/dL, 6.5 mg/dL, and 28.4 mg/dL, respectively, compared to increases from baseline in mean fasting total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> of 1.3 mg/dL and 1mg/dL, and a decrease in triglycerides of 1.1 mg/dL for placebo-treated adolescents. For fasting HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, no clinically meaningful differences were observed between olanzapine-treated adolescents and placebo-treated adolescents.</p>
<p>In long-term studies (at least 24 weeks), adolescents had increases from baseline in mean fasting total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, and triglycerides of 5.5 mg/dL, 5.4 mg/dL, and 20.5 mg/dL, respectively, and a mean decrease in fasting HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> of 4.5 mg/dL. shows categorical changes in fasting lipids values in adolescents.
                                    <span class="Bold">Table 5</span></p>
<p><span class="Bold">Table 5: Changes in Fasting Lipids Values from Adolescent Olanzapine Monotherapy Studies</span></p>
<a name="id_8f64ec21-0c69-4c6b-9015-5d2c39517149"></a><table border="single" width="461">
<col width="13.9%">
<col width="24.2%">
<col width="17.4%">
<col width="11.5%">
<col width="11.6%">
<col width="9.6%">
<col width="11.6%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="3" valign="top"></td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">Up to 6 weeks exposure</span></td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">At least 24 weeks exposure</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Laboratory Analyte</span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Category Change (at least once) from Baseline
                                                    <br></span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Treatment Arm</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">N</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Patients</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">N</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Patients</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="6" valign="middle">Fasting Triglycerides
                                                <br>
</td>
<td class="Botrule Rrule" align="left" rowspan="2" valign="top">Increase by â‰¥50 mg/dL</td>
<td class="Botrule Rrule" align="left" valign="top">Olanzapine</td>
<td class="Botrule Rrule" align="center" valign="top">138</td>
<td class="Botrule Rrule" align="center" valign="top">37%</td>
<td class="Botrule Rrule" align="center" valign="top">122</td>
<td class="Botrule Rrule" align="center" valign="top">45.9%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="top">66</td>
<td class="Botrule Rrule" align="center" valign="top">15.2%</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Normal to High (&lt;90 mg/dL to &gt;130 mg/dL)
                                                <br>
</td>
<td class="Botrule Rrule" align="left" valign="top">Olanzapine</td>
<td class="Botrule Rrule" align="center" valign="top">67</td>
<td class="Botrule Rrule" align="center" valign="top">26.9%</td>
<td class="Botrule Rrule" align="center" valign="top">66</td>
<td class="Botrule Rrule" align="center" valign="top">36.4%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="top">28</td>
<td class="Botrule Rrule" align="center" valign="top">10.7%</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Borderline to High (â‰¥90 mg/dL and â‰¤130 mg/dL to &gt;130 mg/dL)
                                                <br>
</td>
<td class="Botrule Rrule" align="left" valign="top">Olanzapine</td>
<td class="Botrule Rrule" align="center" valign="top">37</td>
<td class="Botrule Rrule" align="center" valign="top">59.5%</td>
<td class="Botrule Rrule" align="center" valign="top">31</td>
<td class="Botrule Rrule" align="center" valign="top">64.5%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="top">17</td>
<td class="Botrule Rrule" align="center" valign="top">35.3%</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="7" valign="top"></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="6" valign="middle">Fasting Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span>
                                                <br>
</td>
<td class="Botrule Rrule" align="left" rowspan="2" valign="top">Increase by â‰¥40 mg/dL</td>
<td class="Botrule Rrule" align="left" valign="top">Olanzapine</td>
<td class="Botrule Rrule" align="center" valign="top">138</td>
<td class="Botrule Rrule" align="center" valign="top">14.5%</td>
<td class="Botrule Rrule" align="center" valign="top">122</td>
<td class="Botrule Rrule" align="center" valign="top">14.8%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="top">66</td>
<td class="Botrule Rrule" align="center" valign="top">4.5%</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Normal to High (&lt;170 mg/dL to â‰¥200 mg/dL)
                                                <br>
</td>
<td class="Botrule Rrule" align="left" valign="top">Olanzapine</td>
<td class="Botrule Rrule" align="center" valign="top">87</td>
<td class="Botrule Rrule" align="center" valign="top">6.9%</td>
<td class="Botrule Rrule" align="center" valign="top">78</td>
<td class="Botrule Rrule" align="center" valign="top">7.7%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="top">43</td>
<td class="Botrule Rrule" align="center" valign="top">2.3%</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Borderline to High (â‰¥170 mg/dL and &lt;200 mg/dL to â‰¥200 mg/dL)
                                                <br>
</td>
<td class="Botrule Rrule" align="left" valign="top">Olanzapine</td>
<td class="Botrule Rrule" align="center" valign="top">36</td>
<td class="Botrule Rrule" align="center" valign="top">38.9%</td>
<td class="Botrule Rrule" align="center" valign="top">33</td>
<td class="Botrule Rrule" align="center" valign="top">57.6%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="top">13</td>
<td class="Botrule Rrule" align="center" valign="top">7.7%</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="7" valign="top"></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="6" valign="middle">Fasting LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span>
                                                <br>
</td>
<td class="Botrule Rrule" align="left" rowspan="2" valign="top">Increase by â‰¥30 mg/dL</td>
<td class="Botrule Rrule" align="left" valign="top">Olanzapine</td>
<td class="Botrule Rrule" align="center" valign="top">137</td>
<td class="Botrule Rrule" align="center" valign="top">17.5%</td>
<td class="Botrule Rrule" align="center" valign="top">121</td>
<td class="Botrule Rrule" align="center" valign="top">22.3%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="top">63</td>
<td class="Botrule Rrule" align="center" valign="top">11.1%</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Normal to High (&lt;110 mg/dL to â‰¥130 mg/dL)
                                                <br>
</td>
<td class="Botrule Rrule" align="left" valign="top">Olanzapine</td>
<td class="Botrule Rrule" align="center" valign="top">98</td>
<td class="Botrule Rrule" align="center" valign="top">5.1%</td>
<td class="Botrule Rrule" align="center" valign="top">92</td>
<td class="Botrule Rrule" align="center" valign="top">10.9%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="top">44</td>
<td class="Botrule Rrule" align="center" valign="top">4.5%</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Borderline to High (â‰¥110 mg/dL and &lt;130 mg/dL to â‰¥130 mg/dL)
                                                <br>
</td>
<td class="Botrule Rrule" align="left" valign="top">Olanzapine</td>
<td class="Botrule Rrule" align="center" valign="top">29</td>
<td class="Botrule Rrule" align="center" valign="top">48.3%</td>
<td class="Botrule Rrule" align="center" valign="top">21</td>
<td class="Botrule Rrule" align="center" valign="top">47.6%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Rrule" align="center" valign="top">9</td>
<td class="Rrule" align="center" valign="top">0%</td>
<td class="Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                                <span class="Sup">a</span>
</td>
</tr>
</tbody>
</table>
<p>Not Applicable.
                                    <span class="Sup">a</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5769fed0-eeeb-40f7-b036-881654461749"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></h2>
<p class="First">Potential consequences of <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> should be considered prior to starting olanzapine. Patients receiving olanzapine should receive regular monitoring of weight .
                                    <span class="Italics">[see Â </span><span class="Bold">PATIENT COUNSELING INFORMATION ( )
                                        <a href="#i4i_section_id_48d74d43-90c2-4ac8-8cef-8ccf7f915193">17.6</a></span><span class="Italics">]</span></p>
<p><span class="Bold"><span class="Italics">Olanzapine Monotherapy in Adults</span></span></p>
<p>In an analysis of 13 placebo-controlled olanzapine monotherapy studies, olanzapine-treated patients gained an average of 2.6 kg (5.7 lb) compared to an average 0.3 kg (0.6 lb) <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> in placebo-treated patients with a median exposure of 6 weeks; 22.2% of olanzapine-treated patients gained at least 7% of their baseline weight, compared to 3% of placebo-treated patients, with a median exposure of 8 weeks; 4.2% of olanzapine-treated patients gained at least 15% of their baseline weight, compared to 0.3% of placebo-treated patients, with a median exposure to event of 12 weeks. Clinically significant <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was observed across all baseline Body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> Index (BMI) categories. Discontinuation due to <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> occurred in 0.2% of olanzapine-treated patients and in 0% of placebo-treated patients.</p>
<p>In long-term studies (at least 48 weeks), the mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was 5.6 kg (12.3 lb) (median exposure of 573 days, N=2021). The percentages of patients who gained at least 7%, 15%, or 25% of their baseline body weight with long-term exposure were 64%, 32%, and 12%, respectively. Discontinuation due to <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> occurred in 0.4% of olanzapine-treated patients following at least 48 weeks of exposure.</p>
<p>includes data on adult <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> with olanzapine pooled from 86 clinical trials. The data in each column represent data for those patients who completed treatment periods of the durations specified.Â 
                                    <span class="Bold">Table
                                        <a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=13640">6</a></span></p>
<p><span class="Bold">Table 6: <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> with Olanzapine Use in Adults</span></p>
<a name="id_0fd3d20d-9ff9-4b04-96d9-4b2a6193ea25"></a><table border="single" width="466">
<col width="22.5%">
<col width="16.5%">
<col width="16.5%">
<col width="16.5%">
<col width="14.0%">
<col width="14.0%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"><span class="Bold">Amount Gained kg (lb)
                                                    <br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">6 Weeks (N=7465) (%)
                                                    <br><br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">6 Months (N=4162) (%)
                                                    <br><br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">12 Months (N=1345) (%)
                                                    <br><br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">24 Months (N=474) (%)
                                                    <br><br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">36 Months (N=147) (%)
                                                    <br><br></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">â‰¤0</td>
<td class="Botrule Rrule" align="center" valign="top">26.2</td>
<td class="Botrule Rrule" align="center" valign="top">24.3</td>
<td class="Botrule Rrule" align="center" valign="top">20.8</td>
<td class="Botrule Rrule" align="center" valign="top">23.2</td>
<td class="Botrule Rrule" align="center" valign="top">17</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">0 to â‰¤5 (0-11 lb)</td>
<td class="Botrule Rrule" align="center" valign="top">57</td>
<td class="Botrule Rrule" align="center" valign="top">36</td>
<td class="Botrule Rrule" align="center" valign="top">26</td>
<td class="Botrule Rrule" align="center" valign="top">23.4</td>
<td class="Botrule Rrule" align="center" valign="top">25.2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">&gt;5 to â‰¤10 (11-22 lb)</td>
<td class="Botrule Rrule" align="center" valign="top">14.9</td>
<td class="Botrule Rrule" align="center" valign="top">24.6</td>
<td class="Botrule Rrule" align="center" valign="top">24.2</td>
<td class="Botrule Rrule" align="center" valign="top">24.1</td>
<td class="Botrule Rrule" align="center" valign="top">18.4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">&gt;10 to â‰¤15 (22-33 lb)</td>
<td class="Botrule Rrule" align="center" valign="top">1.8</td>
<td class="Botrule Rrule" align="center" valign="top">10.9</td>
<td class="Botrule Rrule" align="center" valign="top">14.9</td>
<td class="Botrule Rrule" align="center" valign="top">11.4</td>
<td class="Botrule Rrule" align="center" valign="top">17</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">&gt;15 to â‰¤20 (33-44 lb)</td>
<td class="Botrule Rrule" align="center" valign="top">0.1</td>
<td class="Botrule Rrule" align="center" valign="top">3.1</td>
<td class="Botrule Rrule" align="center" valign="top">8.6</td>
<td class="Botrule Rrule" align="center" valign="top">9.3</td>
<td class="Botrule Rrule" align="center" valign="top">11.6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">&gt;20 to â‰¤25 (44-55 lb)</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule Rrule" align="center" valign="top">0.9</td>
<td class="Botrule Rrule" align="center" valign="top">3.3</td>
<td class="Botrule Rrule" align="center" valign="top">5.1</td>
<td class="Botrule Rrule" align="center" valign="top">4.1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">&gt;25 to â‰¤30 (55-66 lb)</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule Rrule" align="center" valign="top">0.2</td>
<td class="Botrule Rrule" align="center" valign="top">1.4</td>
<td class="Botrule Rrule" align="center" valign="top">2.3</td>
<td class="Botrule Rrule" align="center" valign="top">4.8</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">&gt;30 (&gt;66 lb)</td>
<td class="Rrule" align="center" valign="top">0</td>
<td class="Rrule" align="center" valign="top">0.1</td>
<td class="Rrule" align="center" valign="top">0.8</td>
<td class="Rrule" align="center" valign="top">1.2</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Bold"><span class="Italics">Olanzapine Monotherapy in Adolescents</span></span></span></p>
<p>Â The safety and efficacy of olanzapine for injection have not been established in patients under the age of 18 years. Mean increase in weight in adolescents was greater than in adults. In 4 placebo-controlled trials, discontinuation due to <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> occurred in 1% of olanzapine-treated patients, compared to 0% of placebo-treated patients.</p>
<p><span class="Bold">Table 7: <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> with Olanzapine Use in</span><span class="Bold">Adolescents from 4 Placebo-Controlled Trials</span></p>
<a name="id_f3da6c02-8c97-447b-8561-5171d1468585"></a><table border="single" width="455">
<col width="48.7%">
<col width="27.7%">
<col width="23.7%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Olanzapine-treated patients</span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Placebo-treated patients</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">(median exposure = 3 weeks)
                                                <p class="First">Mean change in body weight from baseline</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">4.6 kg (10.1 lb)</td>
<td class="Botrule Rrule" align="center" valign="top">0.3 kg (0.7 lb)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Percentage of patients who gained at least 7% of baseline body weight</td>
<td class="Botrule Rrule" align="center" valign="top">(median exposure to 7% = 4 weeks)
                                                <p class="First">40.6%</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">(median exposure to 7% = 8 weeks)
                                                <p class="First">9.8%</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Percentage of patients who gained at least 15% of baseline body weight</td>
<td class="Rrule" align="center" valign="top">(median exposure to 15% = 19 weeks)
                                                <p class="First">7.1%</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">(median exposure to 15% = 8 weeks)
                                                <p class="First">2.7%</p>
</td>
</tr>
</tbody>
</table>
<p>In long-term studies (at least 24 weeks), the mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was 11.2 kg (24.6 lb); (median exposure of 201 days, N=179). The percentages of adolescents who gained at least 7%, 15%, or 25% of their baseline body weight with long-term exposure were 89%, 55%, and 29%, respectively. Among adolescent patients, mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> by baseline BMI category was 11.5 kg (25.3 lb), 12.1 kg (26.6 lb), and 12.7 kg (27.9 lb), respectively, for normal (N=106), overweight (N=26) and obese (N=17). Discontinuation due to <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> occurred in 2.2% of olanzapine-treated patients following at least 24 weeks of exposure.</p>
<p>shows data on adolescent <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> with olanzapine pooled from 6 clinical trials. The data in each column represent data for those patients who completed treatment periods of the durations specified. Little clinical trial data is available on <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> in adolescents with olanzapine beyond 6 months of treatment.
                                    <span class="Bold">Table 8</span></p>
<p><span class="Bold">Table 8: <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> with Olanzapine Use in Adolescents</span></p>
<a name="id_ba4d3b04-dceb-4504-bfcd-ca91f115f089"></a><table border="single" width="449">
<col width="35.3%">
<col width="29.9%">
<col width="34.9%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"><span class="Bold">Amount Gained kg (lb)
                                                    <br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">6 Weeks (N=243) (%)
                                                    <br><br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">6 Months (N=191) (%)
                                                    <br><br></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">â‰¤0</td>
<td class="Botrule Rrule" align="center" valign="top">2.9</td>
<td class="Botrule Rrule" align="center" valign="top">2.1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">0 to â‰¤5 (0-11 lb)</td>
<td class="Botrule Rrule" align="center" valign="top">47.3</td>
<td class="Botrule Rrule" align="center" valign="top">24.6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">&gt;5 to â‰¤10 (11-22 lb)</td>
<td class="Botrule Rrule" align="center" valign="top">42.4</td>
<td class="Botrule Rrule" align="center" valign="top">26.7</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">&gt;10 to â‰¤15 (22-33 lb)</td>
<td class="Botrule Rrule" align="center" valign="top">5.8</td>
<td class="Botrule Rrule" align="center" valign="top">22</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">&gt;15 to â‰¤20 (33-44 lb)</td>
<td class="Botrule Rrule" align="center" valign="top">0.8</td>
<td class="Botrule Rrule" align="center" valign="top">12.6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">&gt;20 to â‰¤25 (44-55 lb)</td>
<td class="Botrule Rrule" align="center" valign="top">0.8</td>
<td class="Botrule Rrule" align="center" valign="top">9.4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">&gt;25 to â‰¤30 (55-66 lb)</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule Rrule" align="center" valign="top">2.1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">&gt;30 to â‰¤35 (66-77 lb)</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">&gt;35 to â‰¤40 (77-88 lb)</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">&gt;40 (&gt;88 lb)</td>
<td class="Rrule" align="center" valign="top">0</td>
<td class="Botrule Rrule" align="center" valign="top">0.5</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5ccf6d4e-e5db-4253-b7e1-1d02de28a005"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span></h2>
<p class="First">Â A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> is unknown.</p>
<p>The risk of developing <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses or may even arise after discontinuation of treatment.</p>
<p>There is no known treatment for established cases of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.</p>
<p>Given these considerations, olanzapine should be prescribed in a manner that is most likely to minimize the occurrence of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>. Chronic antipsychotic treatment should generally be reserved for patients (1) who suffer from a chronic illness that is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.</p>
<p>If signs and symptoms of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> appear in a patient on olanzapine, drug discontinuation should be considered. However, some patients may require treatment with olanzapine despite the presence of the syndrome.</p>
<p>For specific information about the warnings of lithium or valproate, refer to the Warnings section of the package inserts for these other products.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_21fd3f46-acca-42c1-b2b9-21545674f9f4"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></h2>
<p class="First">Olanzapine may induce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> associated with <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and, in some patients, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, especially during the initial dose-titration period, probably reflecting its Î± -adrenergic antagonistic properties .
                                    <span class="Sub">1</span><span class="Italics">[see Â </span><span class="Bold">PATIENT COUNSELING INFORMATION ( )
                                        <a href="#i4i_section_id_11946397-d301-4b92-ac42-20196b8f8503">17.7</a></span><span class="Italics">]</span></p>
<p>For oral olanzapine therapy, the risk of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> may be minimized by initiating therapy with 5 mg QD . A more gradual titration to the target dose should be considered if <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs.
                                    <span class="Italics">[see Â </span><span class="Bold">DOSAGE AND ADMINISTRATION (
                                        <a href="#i4i_dosage_admin_id_3cf5f9c6-270f-42d9-ba13-7b3f9a5607dc">2</a></span><span class="Italics">)]</span></p>
<p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> with or without <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> were also reported during the clinical trials with intramuscular olanzapine for injection. In an open-label clinical pharmacology study in nonagitated patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> in which the safety and tolerability of intramuscular olanzapine were evaluated under a maximal dosing regimen (three 10 mg doses administered 4 hours apart), approximately one-third of these patients experienced a significant orthostatic decrease in systolic blood pressure (i.e., decrease â‰¥30 mmHg) . <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> was reported in 0.6% (15/2500) of olanzapine-treated patients in phase 2 to 3 oral olanzapine studies and in 0.3% (2/722) of olanzapine-treated patients with <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> in the intramuscular olanzapine for injection studies. Three normal volunteers in phase 1 studies with intramuscular olanzapine experienced <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and sinus pauses of up to 6 seconds that spontaneously resolved (in 2 cases the reactions occurred on intramuscular olanzapine, and in 1 case, on oral olanzapine). The risk for this sequence of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and sinus pause may be greater in nonpsychiatric patients compared to psychiatric patients who are possibly more adapted to certain effects of psychotropic drugs. For intramuscular Olanzapine for Injection therapy, patients should remain recumbent if drowsy or dizzy after injection until examination has indicated that they are not experiencing <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and/or <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span>.
                                    <span class="Italics">[see Â </span><span class="Bold">DOSAGE AND ADMINISTRATION ( )
                                        <a href="#i4i_section_id_f7e3ec04-6f61-4909-89d3-21577d8fac15">2.4</a></span><span class="Italics">]</span></p>
<p>Olanzapine should be used with particular caution in patients with known cardiovascular disease (history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (<span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, and treatment with antihypertensive medications) where the occurrence of <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> might put the patient at increased medical risk.</p>
<p>Caution is necessary in patients who receive treatment with other drugs having effects that can induce <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, respiratory or central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> . Concomitant administration of intramuscular olanzapine and parenteral benzodiazepine is not recommended due to the potential for excessive sedation and cardiorespiratory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.
                                    <span class="Italics">[see Â </span><span class="Bold">DRUG INTERACTIONS ( )
                                        <a href="#i4i_interactions_id_59a2af3d-f786-459e-84d4-02bc8ff712f1">7</a></span><span class="Italics">]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_60888256-baa2-4481-b8f5-8b6daf727ff2"></a><a name="section-5.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></h2>
<p class="First"><span class="Bold"><span class="Italics">Class Effect</span></span></p>
<p>In clinical trial and/or postmarketing experience, events of <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> have been reported temporally related to antipsychotic agents, including Olanzapine for Injection. <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> has also been reported.</p>
<p>Possible risk factors for <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> include pre-existing low white blood cell count (WBC) and history of drug induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. Patients with a history of a clinically significant low WBC or drug induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of Olanzapine for Injection should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors.</p>
<p>Patients with clinically significant <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should be carefully monitored for <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other symptoms or signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and treated promptly if such symptoms or signs occur. Patients with severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (absolute neutrophil count &lt;1000/mm ) should discontinue Olanzapine for Injection and have their WBC followed until recovery.
                                    <span class="Sup">3</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_58156dc3-d3f8-4d68-b1e6-517f2af3ce36"></a><a name="section-5.10"></a><p></p>
<h2>5.10 <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span></h2>
<p class="First">Esophageal dysmotility and <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> have been associated with antipsychotic drug use. <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">Aspiration pneumonia</span> is a common cause of morbidity and mortality in patients with advanced Alzheimer's disease. Olanzapine is not approved for the treatment of patients with Alzheimer's disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f7e9c39d-c689-47cb-be91-a9fb0f03197d"></a><a name="section-5.11"></a><p></p>
<h2>5.11 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></h2>
<p class="First">During premarketing testing, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> occurred in 0.9% (22/2500) of olanzapine-treated patients. There were confounding factors that may have contributed to the occurrence of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in many of these cases. Olanzapine should be used cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or with conditions that potentially lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold, e.g., Alzheimer's <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. Olanzapine is not approved for the treatment of patients with Alzheimer's disease. Conditions that lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold may be more prevalent in a population of 65 years or older.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_200dd557-0e78-46b9-b86c-c5e866f649e3"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Potential for Cognitive and Motor Impairment</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> was a commonly reported adverse reaction associated with olanzapine treatment, occurring at an incidence of 26% in olanzapine patients compared to 15% in placebo patients. This adverse reaction was also dose related. <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> led to discontinuation in 0.4% (9/2500) of patients in the premarketing database.</p>
<p>Since olanzapine has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that olanzapine therapy does not affect them adversely .
                                    <span class="Italics">[see Â </span><span class="Bold">PATIENT COUNSELING INFORMATION ( )
                                        <a href="#i4i_section_id_343579e0-6b2f-4e57-8374-ec5f4d48bbcd">17.8</a></span><span class="Italics">]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b3fa98c0-e7cb-4c65-9f90-ce75f783e08e"></a><a name="section-5.13"></a><p></p>
<h2>5.13 Body Temperature Regulation</h2>
<p class="First">Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing olanzapine for patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> .
                                    <span class="Italics">[see Â </span><span class="Bold">PATIENT COUNSELING INFORMATION ( )
                                        <a href="#i4i_section_id_4ab3fa87-1a5c-463d-a473-a66f9471ab65">17.9</a></span><span class="Italics">]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_576e9dbd-8b0e-41d7-a537-3f97b646d71f"></a><a name="section-5.14"></a><p></p>
<h2>5.14 Use in Patients with Concomitant Illness</h2>
<p class="First">Clinical experience with olanzapine in patients with certain concomitant systemic illnesses is limited .
                                    <span class="Italics">[see Â </span><span class="Bold">CLINICAL PHARMACOLOGY ( )
                                        <a href="#i4i_pharmacokinetics_id_b00c26eb-c1dd-4dc2-912e-49ce4c3d3ecd">12.3</a></span><span class="Italics">]</span></p>
<p>Olanzapine exhibits muscarinic receptor affinity. In premarketing clinical trials with olanzapine, olanzapine was associated with <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, all adverse reactions possibly related to cholinergic antagonism. Such adverse reactions were not often the basis for discontinuations from olanzapine, but olanzapine should be used with caution in patients with clinically significant <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>, narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, or a history of <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> or related conditions.
                                    <span class="Italics">in vitro</span></p>
<p>In 5 placebo-controlled studies of olanzapine in elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> (n=1184), the following treatment-emergent adverse reactions were reported in olanzapine-treated patients at an incidence of at least 2% and significantly greater than placebo-treated patients: <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, increased weight, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> and <span class="product-label-link" type="condition" conceptid="4275889" conceptname="Visual hallucinations">visual hallucinations</span>. The rate of discontinuation due to adverse reactions was greater with olanzapine than placebo (13% vs 7%). Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with olanzapine are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> compared to placebo. Olanzapine is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> AND .
                                    <span class="Italics">[seeÂ </span><a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=13640">BOXED WARNING</a><span class="Bold">, WARNINGS AND PRECAUTIONS ( )
                                        <a href="#i4i_section_id_617516a7-e25b-4b1e-8645-61d3c78a63d5">5.1</a></span><span class="Bold">PATIENT COUNSELING INFORMATION ( )
                                        <a href="#i4i_section_id_b438b5c0-6445-4cb2-90b5-734f1d3194ac">17.2</a></span><span class="Italics">]</span></p>
<p>Olanzapine has not been evaluated or used to any appreciable extent in patients with a recent history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or unstable heart disease. Patients with these diagnoses were excluded from premarketing clinical studies. Because of the risk of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> with olanzapine, caution should be observed in cardiac patients .
                                    <span class="Italics">[see Â </span><span class="Bold">WARNINGS AND PRECAUTIONS ( )
                                        <a href="#i4i_section_id_21fd3f46-acca-42c1-b2b9-21545674f9f4">5.8</a></span><span class="Italics">]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e0108bdd-04bd-4fa7-8193-61c0a08c3b15"></a><a name="section-5.15"></a><p></p>
<h2>5.15 <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span></h2>
<p class="First">As with other drugs that antagonize dopamine D receptors, olanzapine elevates prolactin levels, and the elevation persists during chronic administration. <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span> may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">Galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> have been reported in patients receiving prolactin-elevating compounds. Long-standing <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">hyperprolactinemia</span> when associated with <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span> may lead to decreased bone density in both female and male subjects.
                                    <span class="Sub">2</span></p>
<p>Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent , a factor of potential importance if the prescription of these drugs is contemplated in a patient with previously detected breast cancer. As is common with compounds which increase prolactin release, an increase in mammary gland neoplasia was observed in the olanzapine carcinogenicity studies conducted in mice and rats . Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans; the available evidence is considered too limited to be conclusive at this time.
                                    <span class="Italics">in vitro</span><span class="Italics">[see Â </span><span class="Bold">NONCLINICAL TOXICOLOGY ( )
                                        <a href="#i4i_carcinogenesis_mutagenesis_fertility_id_29c956ff-094b-486e-9f46-5dc48970f1aa">13.1</a></span><span class="Italics">]</span></p>
<p>In placebo-controlled olanzapine clinical studies (up to 12 weeks), changes from normal to high in prolactin concentrations were observed in 30% of adults treated with olanzapine as compared to 10.5% of adults treated with placebo. In a pooled analysis from clinical studies including 8136 adults treated with olanzapine, potentially associated clinical manifestations included menstrual-related events (2% [49/3240] of females), sexual function-related events (2% [150/8136] of females and males), and breast-related events (0.7% [23/3240] of females, 0.2% [9/4896] of males).
                                    <span class="Sup">1</span><span class="Sup">2</span><span class="Sup">3</span></p>
<p>In placebo-controlled olanzapine monotherapy studies in adolescent patients (up to 6 weeks) with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes), changes from normal to high in prolactin concentrations were observed in 47% of olanzapine-treated patients compared to 7% of placebo-treated patients. In a pooled analysis from clinical trials including 454 adolescents treated with olanzapine, potentially associated clinical manifestations included menstrual-related events (1% [2/168] of females), sexual function-related events (0.7% [3/454] of females and males), and breast-related events (2% [3/168] of females, 2% [7/286] of males) .
                                    <span class="Sup">1</span><span class="Sup">2</span><span class="Sup">3</span><span class="Italics">[see Â </span><span class="Bold">USE IN SPECIFIC POPULATIONS ( )
                                        <a href="#i4i_pediatric_use_id_4ad67cbe-6947-4393-9bb2-37fdbf3742c9">8.4</a></span><span class="Italics">]</span></p>
<p>Based on a search of the following terms: <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4275882" conceptname="Hypomenorrhea">hypomenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4224178" conceptname="Menstrual period late">menstruation delayed</span>, and <span class="product-label-link" type="condition" conceptid="442274" conceptname="Oligomenorrhea">oligomenorrhea</span>.
                                    <span class="Sup">1</span></p>
<p>Based on a search of the following terms: <span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">anorgasmia</span>, delayed ejaculation, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, decreased libido, <span class="product-label-link" type="condition" conceptid="4087317" conceptname="Lack of libido">loss of libido</span>, abnormal orgasm, and <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span>.
                                    <span class="Sup">2</span></p>
<p>Based on a search of the following terms: <span class="product-label-link" type="condition" conceptid="4181744" conceptname="Discharge from nipple">breast discharge</span>, enlargement or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, and <span class="product-label-link" type="condition" conceptid="80471" conceptname="Disorder of lactation">lactation disorder</span>.
                                    <span class="Sup">3</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_13de78d4-a97d-4881-b8d2-474d5cd0832f"></a><a name="section-5.16"></a><p></p>
<h2>5.16 Use in Combination with Lithium, or Valproate</h2>
<p class="First">When using Olanzapine in combination with lithium or valproate, the prescriber should refer to the Warnings and Precautions sections of the package inserts for lithium or valproate .
                                    <span class="Italics">[see Â </span><span class="Bold">DRUG INTERACTIONS ( )
                                        <a href="#i4i_interactions_id_59a2af3d-f786-459e-84d4-02bc8ff712f1">7</a></span><span class="Italics">]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_393e8125-cf30-4c4c-9b49-181c837755c4"></a><a name="section-5.17"></a><p></p>
<h2>5.17 Laboratory Tests</h2>
<p class="First">Fasting blood glucose testing and lipid profile at the beginning of, and periodically during, treatment is recommended AND .
                                    <span class="Italics">[see Â </span><span class="Bold">WARNINGS AND PRECAUTIONS ( , )
                                        <a href="#i4i_section_id_5fc99f10-df4d-4ed4-870e-dfe1f1a64919">5.4</a><a href="#i4i_section_id_124564fe-51e9-46ca-a1ce-7dc43aa9fb93">5.5</a></span><span class="Bold">PATIENT COUNSELING INFORMATION ( , )
                                        <a href="#i4i_section_id_67eab0e9-3f5e-48ac-ab86-2a94b1872e60">17.4</a><a href="#i4i_section_id_8e84e0b7-f47c-4c8d-8501-55752474fbed">17.5</a></span><span class="Italics">]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_dc884a3e-7fb5-4d58-85ee-92f5dc0d37ad"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_37eec9e2-7d97-4bcb-8b21-ae53cb43b852"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect or predict the rates observed in practice.</p>
<p>Â 
                                    <span class="Bold"><span class="Italics">Clinical Trials in Adults</span></span></p>
<p>The information below for Olanzapine is derived from a clinical trial database for Olanzapine consisting of 8661 adult patients with approximately 4165 patient-years of exposure to oral Olanzapine and 722 patients with exposure to intramuscular Olanzapine for Injection. This database includes: (1) 2500 patients who participated in multiple-dose oral olanzapine premarketing trials in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and Alzheimer's disease representing approximately 1122 patient-years of exposure as of February 14, 1995; (2) 182 patients who participated in oral Olanzapine premarketing <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes) trials representing approximately 66 patient-years of exposure; (3) 191 patients who participated in an oral Olanzapine trial of patients having various <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span> in association with Alzheimer's disease representing approximately 29 patient-years of exposure; (4) 5788 patients from 88 additional oral Olanzapine clinical trials as of December 31, 2001; and (5) 722 patients who participated in intramuscular Olanzapine for Injection premarketing trials in <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes), or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. In addition, information from the premarketing 6-week clinical study database for olanzapine in combination with lithium or valproate, consisting of 224 patients who participated in <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes) trials with approximately 22 patient-years of exposure, is included below.</p>
<p>The conditions and duration of treatment with Olanzapine varied greatly and included (in overlapping categories) open-label and double-blind phases of studies, inpatients and outpatients, fixed-dose and dose-titration studies, and short-term or longer-term exposure. Adverse reactions were assessed by collecting adverse reactions, results of physical examinations, vital signs, weights, laboratory analytes, ECGs, chest x-rays, and results of ophthalmologic examinations.</p>
<p>Certain portions of the discussion below relating to objective or numeric safety parameters, namely, dose-dependent adverse reactions, vital sign changes, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, laboratory changes, and ECG changes are derived from studies in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and have not been duplicated for <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes) or <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>. However, this information is also generally applicable to <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes) and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>.</p>
<p>Adverse reactions during exposure were obtained by spontaneous report and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse reactions without first grouping similar types of reactions into a smaller number of standardized reaction categories. In the tables and tabulations that follow, MedDRA and COSTART Dictionary terminology has been used to classify reported adverse reactions.</p>
<p>The stated frequencies of adverse reactions represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse reaction of the type listed. A reaction was considered treatment emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. The reported reactions do not include those reaction terms that were so general as to be uninformative. Reactions listed elsewhere in labeling may not be repeated below. It is important to emphasize that, although the reactions occurred during treatment with olanzapine, they were not necessarily caused by it. The entire label should be read to gain a complete understanding of the safety profile of olanzapine.</p>
<p>The prescriber should be aware that the figures in the tables and tabulations cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and nondrug factors to the adverse reactions incidence in the population studied.</p>
<p><span class="Italics">Incidence of Adverse Reactions in Short-Term, Placebo-Controlled and Combination Trials</span></p>
<p>The following findings are based on premarketing trials of (1) oral olanzapine for <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes), a subsequent trial of patients having various <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span> in association with Alzheimer's disease, and premarketing combination trials, and (2) intramuscular olanzapine for injection in <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or bipolar I <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>.</p>
<p><span class="Italics">Adverse Reactions Associated with Discontinuation of Treatment in Short-Term, Placebo-Controlled Trials</span></p>
<p>â€” Overall, there was no difference in the incidence of discontinuation due to adverse reactions (5% for oral olanzapine vs 6% for placebo). However, discontinuations due to increases in ALT were considered to be drug related (2% for oral olanzapine vs 0% for placebo).
                                    <span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></span></p>
<p>â€” Overall, there was no difference in the incidence of discontinuation due to adverse reactions (2% for oral olanzapine vs 2% for placebo).
                                    <span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> or Mixed Episodes) Monotherapy</span></span></p>
<p>- Overall, there was no difference in the incidence of discontinuation due to adverse reactions (0.4% for intramuscular olanzapine for injection vs 0% for placebo).
                                    <span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span></span></span></p>
<p><span class="Italics">Adverse Reactions Associated with Discontinuation of Treatment in Short-Term Combination Trials</span></p>
<p>â€” In a study of patients who were already tolerating either lithium or valproate as monotherapy, discontinuation rates due to adverse reactions were 11% for the combination of oral olanzapine with lithium or valproate compared to 2% for patients who remained on lithium or valproate monotherapy. Discontinuations with the combination of oral olanzapine and lithium or valproate that occurred in more than 1 patient were: <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (3%), <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> (1%), and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> (1%).
                                    <span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> or Mixed Episodes), Olanzapine as Adjunct to Lithium or Valproate</span></span></p>
<p><span class="Italics">Commonly Observed Adverse Reactions in Short-Term, Placebo-Controlled Trials</span></p>
<p>The most commonly observed adverse reactions associated with the use of oral olanzapine (incidence of 5% or greater) and not observed at an equivalent incidence among placebo-treated patients (olanzapine incidence at least twice that for placebo) were:</p>
<p><span class="Bold">Table 9: Common Treatment-Emergent Adverse Reactions Associated</span></p>
<p><span class="Bold">with the</span><span class="Bold">Use of Oral Olanzapine in 6-Week Trials â€” <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">SCHIZOPHRENIA</span></span></p>
<a name="id_309b3915-1f68-42d5-9eef-ee620c305d59"></a><table border="single" width="419">
<col width="43.7%">
<col width="43.9%">
<col width="12.4%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top"><p class="First"><span class="Bold">Percentage of Patients Reporting Event</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Olanzapine</span></p>
<span class="Bold">(N=248)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<span class="Bold">(N=118)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Postural hypotension</span></td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span></td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">Personality disorder</span>
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span></td>
<td class="Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">Personality disorder</span> is the COSTART term for designating nonaggressive objectionable behavior.
                                    <span class="Sup">a</span></p>
<p><span class="Bold">Table 10: Common Treatment-Emergent Adverse Reactions Associated with the</span><span class="Bold">Use of Oral Olanzapine in 3-Week and 4-Week Trials â€” <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> or Mixed Episodes)</span></p>
<a name="id_f5ede408-b63d-4cc5-931a-f58fdb11cd39"></a><table border="single" width="419">
<col width="43.7%">
<col width="43.9%">
<col width="12.4%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top"><p class="First"><span class="Bold">Percentage of Patients Reporting Event</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Olanzapine</span></p>
<span class="Bold">(N=125)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<span class="Bold">(N=129)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Botrule Rrule" align="center" valign="top">15</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></td>
<td class="Botrule Rrule" align="center" valign="top">22</td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span></td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Botrule Rrule" align="center" valign="top">35</td>
<td class="Botrule Rrule" align="center" valign="top">13</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Rrule" align="center" valign="top">18</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td class="Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
</tbody>
</table>
<p>â€” There was 1 adverse reaction (<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>) observed at an incidence of 5% or greater among intramuscular olanzapine for injection-treated patients and not observed at an equivalent incidence among placebo-treated patients (olanzapine incidence at least twice that for placebo) during the placebo-controlled premarketing studies. The incidence of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> during the 24 hour IM treatment period in clinical trials in <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or bipolar I <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> was 6% for intramuscular olanzapine for injection and 3% for placebo.
                                    <span class="Italics">Olanzapine Intramuscular</span></p>
<p><span class="Italics">Adverse Reactions Occurring at an Incidence of 2% or More among Oral Olanzapine-Treated Patients in Short-Term,</span><span class="Italics">Placebo-Controlled Trials</span></p>
<p>enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse reactions that occurred in 2% or more of patients treated with oral olanzapine (doses â‰¥2.5 mg/day) and with incidence greater than placebo who participated in the acute phase of placebo-controlled trials.
                                    <span class="Bold">Table 11</span></p>
<p><span class="Bold">Table 11: Treatment-Emergent Adverse Reactions:</span><span class="Bold">Incidence in Short-Term, Placebo-Controlled Clinical Trials with Oral Olanzapine</span></p>
<a name="id_833a7b53-48fb-4429-9e98-e36df9de5ff0"></a><table border="single" width="410">
<col width="43.7%">
<col width="39.5%">
<col width="16.8%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top"><p class="First"><span class="Bold">Percentage of Patients Reporting Event</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Body System/Adverse Reaction</span></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Olanzapine</span></p>
<span class="Bold">(N=532)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<span class="Bold">(N=294)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Body as a Whole</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental injury</span></td>
<td class="Botrule Rrule" align="center" valign="top">12</td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Botrule Rrule" align="center" valign="top">10</td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Cardiovascular System</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Postural hypotension</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Digestive System</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Hemic and Lymphatic System</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span></td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Metabolic and Nutritional Disorders</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span></td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Musculoskeletal System</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Extremity <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (other than joint)</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Joint pain</span></td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Nervous System</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Botrule Rrule" align="center" valign="top">29</td>
<td class="Botrule Rrule" align="center" valign="top">13</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Botrule Rrule" align="center" valign="top">12</td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Abnormal gait</span></td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">Hypertonia</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Articulation impairment</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Respiratory System</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough increased</span></td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Special Senses</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">Amblyopia</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Urogenital System</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">Urinary incontinence</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td class="Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
</tbody>
</table>
<p><span class="Italics">Commonly Observed Adverse Reactions in Short-Term Trials  of Oral Olanzapine as Adjunct to Lithium or Valproate</span></p>
<p>In the <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes) adjunct placebo-controlled trials, the most commonly observed adverse reactions associated with the combination of olanzapine and lithium or valproate (incidence of â‰¥5% and at least twice placebo) were:</p>
<p><span class="Bold">Table 12: Common Treatment-Emergent Adverse Reactions Associated with the</span><span class="Bold">Use of Oral Olanzapine in 6-Week Adjunct to Lithium or Valproate Trials â€” <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> or Mixed Episodes)</span></p>
<a name="id_14860a7a-0b95-4ac9-812f-60398206ce41"></a><table border="single" width="431">
<col width="42.5%">
<col width="38.1%">
<col width="19.4%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top"><p class="First"><span class="Bold">Percentage of Patients Reporting Event</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Olanzapine with</span></p>
<p><span class="Bold">lithium or valproate</span></p>
<span class="Bold">(N=229)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Placebo with lithium or valproate (N=115)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Botrule Rrule" align="center" valign="top">32</td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span></td>
<td class="Botrule Rrule" align="center" valign="top">26</td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span></td>
<td class="Botrule Rrule" align="center" valign="top">24</td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Rrule" align="center" valign="top">14</td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Speech disorder</td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Increased salivation</span></td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td class="Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
</tbody>
</table>
<p><span class="Italics">Adverse Reactions Occurring at an Incidence of 2% or More among Oral Olanzapine-Treated Patients in Short-Term Trials</span><span class="Italics">of Olanzapine as Adjunct to Lithium or Valproate</span></p>
<p>enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse reactions that occurred in 2% or more of patients treated with the combination of olanzapine (doses â‰¥5 mg/day) and lithium or valproate and with incidence greater than lithium or valproate alone who participated in the acute phase of placebo-controlled combination trials.
                                    <span class="Bold">Table 13</span></p>
<p><span class="Bold">Table 13: Treatment-Emergent Adverse Reactions: Incidence in Short-Term, Placebo-Controlled Clinical Trials of</span><span class="Bold">Oral Olanzapine as Adjunct to Lithium or Valproate</span></p>
<a name="id_da7b6ed8-5841-4a52-be18-4c980e1f1614"></a><table border="single" width="437">
<col width="41.9%">
<col width="33.4%">
<col width="24.7%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top"><span class="Bold">Percentage of Patients Reporting Event</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Body System/Adverse Reaction</span></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Olanzapine with lithium or valproate</span></p>
<p><span class="Bold">(N=229)</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo with lithium or</span></p>
<p><span class="Bold">valproate</span></p>
<p><span class="Bold">(N=115)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Body as a Whole</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Botrule Rrule" align="center" valign="top">18</td>
<td class="Botrule Rrule" align="center" valign="top">13</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental injury</span></td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Cardiovascular System</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Digestive System</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Botrule Rrule" align="center" valign="top">32</td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span></td>
<td class="Botrule Rrule" align="center" valign="top">24</td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">Thirst</span></td>
<td class="Botrule Rrule" align="center" valign="top">10</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Increased salivation</span></td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Metabolic and Nutritional Disorders</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span></td>
<td class="Botrule Rrule" align="center" valign="top">26</td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span></p></td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Nervous System</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Botrule Rrule" align="center" valign="top">52</td>
<td class="Botrule Rrule" align="center" valign="top">27</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td class="Botrule Rrule" align="center" valign="top">23</td>
<td class="Botrule Rrule" align="center" valign="top">13</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Botrule Rrule" align="center" valign="top">18</td>
<td class="Botrule Rrule" align="center" valign="top">17</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Rrule" align="center" valign="top">14</td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Speech Disorder</td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span></td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">Apathy</span></td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">Euphoria</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">Incoordination</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Respiratory System</span></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Skin and Appendages</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry Skin</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Special Senses</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">Amblyopia</span></td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Abnormal vision</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Urogenital System</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">Dysmenorrhea</span>
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span>
                                                <span class="Sup">a</span>
</td>
<td class="Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
</tbody>
</table>
<p>Denominator used was for females only (olanzapine, N=128; placebo, N=51).
                                    <span class="Sup">a</span></p>
<p>For specific information about the adverse reactions observed with lithium or valproate, refer to the Adverse Reactions section of the package inserts for these other products.</p>
<p><span class="Italics">Adverse Reactions Occurring at an Incidence of 1% or More among Intramuscular Olanzapine for Injection-Treated Patients</span><span class="Italics">in  Short-Term, Placebo-Controlled Trials</span></p>
<p>enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse reactions that occurred in 1% or more of patients treated with intramuscular olanzapine for injection (dose range of 2.5 to 10 mg/injection) and with incidence greater than placebo who participated in the short-term, placebo-controlled trials in <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or bipolar I <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>.
                                    <span class="Bold">Table 14</span></p>
<p><span class="Bold">Table 14: Treatment-Emergent Adverse Reactions: Incidence in Short-Term (24 Hour), Placebo-Controlled Clinical Trials</span><span class="Bold">with Intramuscular Olanzapine for Injection in <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitated</span> Patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> or Bipolar I <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></span></p>
<a name="id_51987d58-e9f3-43e5-835a-c15693760c0b"></a><table border="single" width="415">
<col width="44.2%">
<col width="44.3%">
<col width="11.5%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Percentage of Patients Reporting Event</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Body System/Adverse Reaction</span></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Olanzapine</span></p>
<span class="Bold">(N=415)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<span class="Bold">(N=150)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Body as a Whole</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Cardiovascular System</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Postural hypotension</span></td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Nervous System</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td class="Rrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Italics">Additional Findings Observed in Clinical Trials</span></span></p>
<p><span class="Italics">Dose Dependency of Adverse Reactions in Short-Term, Placebo-Controlled Trials</span></p>
<p>The following table enumerates the percentage of patients with treatment-emergent <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> as assessed by categorical analyses of formal rating scales during acute therapy in a controlled clinical trial comparing oral olanzapine at 3 fixed doses with placebo in the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> in a 6-week trial.
                                    <span class="Italics">:
                                        <span class="Underline"><span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span></span></span></p>
<p><span class="Bold">Table 15: Treatment-Emergent <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span> Assessed by Rating Scales Incidence</span><span class="Bold">in a Fixed Dosage Range, Placebo-Controlled Clinical Trial of Oral Olanzapine in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> â€” Acute Phase</span></p>
<a name="id_7e2a7222-421b-4b57-8bb5-8a577d9e9e7a"></a><table border="single" width="443">
<col width="17.3%">
<col width="17.2%">
<col width="21.0%">
<col width="20.4%">
<col width="24.1%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="4" valign="top"><span class="Bold">Percentage of Patients Reporting Event</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><span class="Bold">Placebo</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Olanzapine 5Â±2.5 mg/day
                                                    <br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Olanzapine 10Â±2.5 mg/day
                                                    <br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Olanzapine 15Â±2.5 mg/day
                                                    <br></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="justify" valign="top"><span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span>
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">15</td>
<td class="Botrule Rrule" align="center" valign="top">14</td>
<td class="Botrule Rrule" align="center" valign="top">12</td>
<td class="Botrule Rrule" align="center" valign="top">14</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="justify" valign="top"><span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span>
                                                <span class="Sup">b</span>
</td>
<td class="Rrule" align="center" valign="top">23</td>
<td class="Rrule" align="center" valign="top">16</td>
<td class="Rrule" align="center" valign="top">19</td>
<td class="Botrule Rrule" align="center" valign="top">27</td>
</tr>
</tbody>
</table>
<p>Percentage of patients with a Simpson-Angus Scale total score &gt;3.
                                    <span class="Sup">a</span></p>
<p>Percentage of patients with a Barnes <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> Scale global score â‰¥2.
                                    <span class="Sup">b</span></p>
<p>The following table enumerates the percentage of patients with treatment-emergent <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> as assessed by spontaneously reported adverse reactions during acute therapy in the same controlled clinical trial comparing olanzapine at 3 fixed doses with placebo in the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> in a 6-week trial.</p>
<p><span class="Bold">Table 16: Treatment-Emergent <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span> Assessed by Adverse Reactions Incidence</span><span class="Bold">in a Fixed Dosage Range, Placebo-Controlled Clinical Trial of Oral Olanzapine in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> â€” Acute Phase</span></p>
<a name="id_ca4050b3-8dbd-4535-a696-50f77a205646"></a><table border="single" width="482">
<col width="24.3%">
<col width="12.1%">
<col width="21.5%">
<col width="21.5%">
<col width="20.5%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="4" valign="top"><span class="Bold">Percentage of Patients Reporting Event</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<span class="Bold">(N=68)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Olanzapine</span></p>
<p><span class="Bold">5 Â± 2.5 mg/day</span></p>
<span class="Bold">(N=65)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Olanzapine</span></p>
<p><span class="Bold">10 Â± 2.5 mg/day</span></p>
<span class="Bold">(N=64)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Olanzapine</span></p>
<p><span class="Bold">15 Â± 2.5 mg/day</span></p>
<span class="Bold">(N=69)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Dystonic events
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span> events
                                                <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">10</td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
<td class="Botrule Rrule" align="center" valign="top">14</td>
<td class="Botrule Rrule" align="center" valign="top">20</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> events
                                                <span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
<td class="Botrule Rrule" align="center" valign="top">10</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Dyskinetic events
                                                <span class="Sup">d</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Residual events
                                                <span class="Sup">e</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Any extrapyramidal event</td>
<td class="Rrule" align="center" valign="top">16</td>
<td class="Rrule" align="center" valign="top">15</td>
<td class="Rrule" align="center" valign="top">25</td>
<td class="Botrule Rrule" align="center" valign="top">32</td>
</tr>
</tbody>
</table>
<p>Patients with the following COSTART terms were counted in this category: <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">generalized spasm</span>, <span class="product-label-link" type="condition" conceptid="4228784" conceptname="Nuchal rigidity">neck rigidity</span>, <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyric crisis</span>, <span class="product-label-link" type="condition" conceptid="4313849" conceptname="Opisthotonus">opisthotonos</span>, <span class="product-label-link" type="condition" conceptid="440814" conceptname="Torticollis">torticollis</span>.
                                    <span class="Sup">a</span></p>
<p>Patients with the following COSTART terms were counted in this category: <span class="product-label-link" type="condition" conceptid="4143471" conceptname="Akinesia">akinesia</span>, <span class="product-label-link" type="condition" conceptid="4208094" conceptname="Cogwheel muscle rigidity">cogwheel rigidity</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal syndrome</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="4013001" conceptname="Masklike facies">masked facies</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>.
                                    <span class="Sup">b</span></p>
<p>Patients with the following COSTART terms were counted in this category: <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>.
                                    <span class="Sup">c</span></p>
<p>Patients with the following COSTART terms were counted in this category: buccoglossal syndrome, <span class="product-label-link" type="condition" conceptid="4181630" conceptname="Choreoathetosis">choreoathetosis</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>.
                                    <span class="Sup">d</span></p>
<p>Patients with the following COSTART terms were counted in this category: <span class="product-label-link" type="condition" conceptid="372604" conceptname="Movement disorder">movement disorder</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>.
                                    <span class="Sup">e</span></p>
<p>The following table enumerates the percentage of adolescent patients with treatment-emergent <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> as assessed by spontaneously reported adverse reactions during acute therapy (dose range: 2.5 to 20 mg/day).</p>
<p><span class="Bold">Table 17: Treatment-Emergent <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span> Assessed by Adverse Reactions Incidence</span><span class="Bold">in Placebo-Controlled Clinical Trials of Oral Olanzapine in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> and <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> â€” Adolescents</span></p>
<a name="id_19f62baa-33f6-43c9-8bb8-df68c627f264"></a><table border="single" width="406">
<col width="28.2%">
<col width="27.5%">
<col width="44.3%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"><span class="Bold">Categories
                                                    <span class="Sup">a</span></span></td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">Percentage of Patients Reporting Event</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><span class="Bold">Placebo (N=89)</span></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Olanzapine</span></p>
<span class="Bold">(N=179)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Dystonic events</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span> events</td>
<td class="Botrule Rrule" align="center" valign="middle">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> events</td>
<td class="Botrule Rrule" align="center" valign="middle">4</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Dyskinetic events</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Nonspecific events</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Any extrapyramidal event</td>
<td class="Rrule" align="center" valign="middle">6</td>
<td class="Botrule Rrule" align="center" valign="top">10</td>
</tr>
</tbody>
</table>
<p>Categories are based on Standard MedDRA Queries (SMQ) for <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> as defined in MedDRA version 12.0.
                                    <span class="Sup">a</span></p>
<p>The following table enumerates the percentage of patients with treatment-emergent <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> as assessed by categorical analyses of formal rating scales during controlled clinical trials comparing fixed doses of intramuscular olanzapine for injection with placebo in <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>. Patients in each dose group could receive up to 3 injections during the trials . Patient assessments were conducted during the 24 hours following the initial dose of intramuscular olanzapine for injection.
                                    <span class="Italics">[see Â </span><span class="Bold">CLINICAL STUDIES ( )
                                        <a href="#i4i_section_id_d44b2269-6f37-4812-be3e-8301e967a954">14.3</a></span><span class="Italics">]</span></p>
<p><span class="Bold">Table 18: Treatment-Emergent <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span> Assessed by Rating Scales Incidence in a Fixed Dose, Placebo-Controlled Clinical Trial of Intramuscular Olanzapine for Injection in <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitated</span> Patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></p>
<a name="id_3eba4fd5-88d1-435f-a141-b56460566f9f"></a><table border="single" width="443">
<col width="17.0%">
<col width="16.1%">
<col width="16.7%">
<col width="16.7%">
<col width="16.7%">
<col width="16.7%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="5" valign="top"><span class="Bold">Percentage of Patients Reporting Event</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><span class="Bold">Placebo</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Olanzapine IM 2.5 mg
                                                    <br><br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Olanzapine IM 5 mg
                                                    <br><br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Olanzapine IM 7.5 mg
                                                    <br><br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Olanzapine IM 10 mg
                                                    <br><br></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span>
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">3</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span>
                                                <span class="Sup">b</span>
</td>
<td class="Rrule" align="center" valign="middle">0</td>
<td class="Rrule" align="center" valign="middle">0</td>
<td class="Rrule" align="center" valign="middle">5</td>
<td class="Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
</tr>
</tbody>
</table>
<p>Percentage of patients with a Simpson-Angus Scale total score &gt;3.
                                    <span class="Sup">a</span></p>
<p>Percentage of patients with a Barnes <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> Scale global score â‰¥2.
                                    <span class="Sup">b</span></p>
<p>The following table enumerates the percentage of patients with treatment-emergent <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> as assessed by spontaneously reported adverse reactions in the same controlled clinical trial comparing fixed doses of intramuscular Olanzapine for Injection with placebo in <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>.</p>
<p><span class="Bold">Table 19: Treatment-Emergent <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span> Assessed by Adverse Reactions Incidence in a Fixed Dose, Placebo-Controlled Clinical Trial of Intramuscular Olanzapine for Injection in <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitated</span> Patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></p>
<a name="id_ca3efe1d-86c0-45af-8a68-f5e091e4dfc8"></a><table border="single" width="495">
<col width="25.2%">
<col width="10.8%">
<col width="15.4%">
<col width="15.6%">
<col width="16.6%">
<col width="16.4%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="5" valign="top"><span class="Bold">Percentage of Patients Reporting Event</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">Placebo (N=45)
                                                    <br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Olanzapine IM 2.5 mg (N=48)
                                                    <br><br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Olanzapine IM 5 mg (N=45)
                                                    <br><br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Olanzapine IM 7.5 mg (N=46)
                                                    <br><br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Olanzapine IM 10 mg (N=46)
                                                    <br><br></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Dystonic events
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span> events
                                                <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">4</td>
<td class="Botrule Rrule" align="center" valign="middle">2</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> events
                                                <span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">2</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Dyskinetic events
                                                <span class="Sup">d</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Residual events
                                                <span class="Sup">e</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Any extrapyramidal events</td>
<td class="Rrule" align="center" valign="middle">0</td>
<td class="Rrule" align="center" valign="middle">4</td>
<td class="Rrule" align="center" valign="middle">2</td>
<td class="Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
</tr>
</tbody>
</table>
<p>Patients with the following COSTART terms were counted in this category: <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">generalized spasm</span>, <span class="product-label-link" type="condition" conceptid="4228784" conceptname="Nuchal rigidity">neck rigidity</span>, <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyric crisis</span>, <span class="product-label-link" type="condition" conceptid="4313849" conceptname="Opisthotonus">opisthotonos</span>, <span class="product-label-link" type="condition" conceptid="440814" conceptname="Torticollis">torticollis</span>.
                                    <span class="Sup">a</span></p>
<p>Patients with the following COSTART terms were counted in this category: <span class="product-label-link" type="condition" conceptid="4143471" conceptname="Akinesia">akinesia</span>, <span class="product-label-link" type="condition" conceptid="4208094" conceptname="Cogwheel muscle rigidity">cogwheel rigidity</span>,  <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal syndrome</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="4013001" conceptname="Masklike facies">masked facies</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>.
                                    <span class="Sup">b</span></p>
<p>Patients with the following COSTART terms were counted in this category: <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>.
                                    <span class="Sup">c</span></p>
<p>Patients with the following COSTART terms were counted in this category: buccoglossal syndrome, <span class="product-label-link" type="condition" conceptid="4181630" conceptname="Choreoathetosis">choreoathetosis</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>.
                                    <span class="Sup">d</span></p>
<p>Patients with the following COSTART terms were counted in this category: <span class="product-label-link" type="condition" conceptid="372604" conceptname="Movement disorder">movement disorder</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>.
                                    <span class="Sup">e</span></p>
<p>Symptoms of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, and/or protrusion of the tongue. While these symptoms can occur at low doses, the frequency and severity are greater with high potency and at higher doses of first generation antipsychotic drugs. In general, an elevated risk of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">acute dystonia</span> may be observed in males and younger age groups receiving antipsychotics; however, events of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span> have been reported infrequently (&lt;1%) with olanzapine use.
                                    <span class="Italics">:
                                        <span class="Underline"><span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span>, Class Effect</span></span></p>
<p>The following table addresses dose relatedness for other adverse reactions using data from a <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> trial involving fixed dosage ranges of oral olanzapine. It enumerates the percentage of patients with treatment-emergent adverse reactions for the 3 fixed-dose range groups and placebo. The data were analyzed using the Cochran-Armitage test, excluding the placebo group, and the table includes only those adverse reactions for which there was a trend.
                                    <span class="Italics">:
                                        <span class="Underline">Other Adverse Reactions</span></span></p>
<p><span class="Bold">Table 20: Percentage of Patients from a <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> Trial with Treatment-Emergent Adverse Reactions for the 3 Dose Range Groups and Placebo</span></p>
<a name="id_ff520bde-43b9-4c30-a525-3106cdd651f7"></a><table border="single" width="443">
<col width="20.1%">
<col width="19.7%">
<col width="20.1%">
<col width="20.1%">
<col width="20.1%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Rrule" align="center" colspan="4" valign="top"><span class="Bold">Percentage of Patients Reporting Event</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><span class="Bold">Placebo (N=68)
                                                    <br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Olanzapine 5 Â± 2.5 mg/day (N=65)
                                                    <br><br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Olanzapine 10 Â± 2.5 mg/day (N=64)
                                                    <br><br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Olanzapine 15 Â± 2.5 mg/day (N=69)
                                                    <br><br></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Botrule Rrule" align="center" valign="middle">15</td>
<td class="Botrule Rrule" align="center" valign="middle">8</td>
<td class="Botrule Rrule" align="center" valign="middle">9</td>
<td class="Botrule Rrule" align="center" valign="middle">20</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Botrule Rrule" align="center" valign="middle">4</td>
<td class="Botrule Rrule" align="center" valign="middle">3</td>
<td class="Botrule Rrule" align="center" valign="middle">5</td>
<td class="Botrule Rrule" align="center" valign="middle">13</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Rrule" align="center" valign="middle">9</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">2</td>
<td class="Botrule Rrule" align="center" valign="middle">9</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Botrule Rrule" align="center" valign="middle">16</td>
<td class="Botrule Rrule" align="center" valign="middle">20</td>
<td class="Botrule Rrule" align="center" valign="middle">30</td>
<td class="Botrule Rrule" align="center" valign="middle">39</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td class="Rrule" align="center" valign="middle">3</td>
<td class="Rrule" align="center" valign="middle">0</td>
<td class="Rrule" align="center" valign="middle">5</td>
<td class="Botrule Rrule" align="center" valign="middle">7</td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Bold"><span class="Italics">Differences among Fixed-Dose Groups Observed in Other Olanzapine Clinical Trials</span></span></span></p>
<p>Â In a single 8-week randomized, double-blind, fixed-dose study comparing 10 (N=199), 20 (N=200) and 40 (N=200) mg/day of oral olanzapine in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">schizoaffective disorder</span>, differences among 3 dose groups were observed for the following safety outcomes: <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, prolactin elevation, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. Mean baseline to endpoint increase in weight (10 mg/day: 1.9 kg; 20 mg/day: 2.3 kg; 40 mg/day: 3 kg) was observed with significant differences between 10 vs 40 mg/day. Incidence of treatment-emergent prolactin elevation &gt;24.2 ng/mL (female) or &gt;18.77 ng/mL (male) at any time during the trial (10 mg/day: 31.2%; 20 mg/day: 42.7%; 40 mg/day: 61.1%) with significant differences between 10 vs 40 mg/day and 20 vs 40 mg/day; <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (10 mg/day: 1.5%; 20 mg/day: 2.1%; 40 mg/day: 6.6%) with significant differences between 10 vs 40 and 20 vs 40 mg/day; and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (10 mg/day: 2.6%; 20 mg/day: 1.6%; 40 mg/day: 6.6%) with significant differences between 20 vs 40 mg, was observed.</p>
<p><span class="Bold"><span class="Italics">Other Adverse Reactions Observed During the Clinical Trial Evaluation of Oral Olanzapine</span></span></p>
<p>Following is a list of treatment-emergent adverse reactions reported by patients treated with oral olanzapine (at multiple doses â‰¥1 mg/day) in clinical trials. This listing is not intended to include reactions (1) already listed in previous tables or elsewhere in labeling, (2) for which a drug cause was remote, (3) which were so general as to be uninformative, (4) which were not considered to have significant clinical implications, or (5) which occurred at a rate equal to or less than placebo. Reactions are classified by body system using the following definitions: frequent adverse reactions are those occurring in at least 1/100 patients; infrequent adverse reactions are those occurring in 1/100 to 1/1000 patients; rare reactions are those occurring in fewer than 1/1000 patients.</p>
<p>â€” <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>, <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span> ; <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4137607" conceptname="Hangover">hangover effect</span>, <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> .
                                    <span class="Bold">Body as a Whole</span><span class="Italics">Infrequent:</span><span class="Sup">1</span><span class="Italics">Rare:</span><span class="Sup">1</span></p>
<p>â€” <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>.
                                    <span class="Bold">Cardiovascular System</span><span class="Italics">Infrequent:</span></p>
<p>â€” <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4217627" conceptname="Edema of the tongue">tongue edema</span>; <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">liver fatty deposit</span>.
                                    <span class="Bold">Digestive System</span><span class="Italics">Infrequent:</span><span class="Italics">Rare:</span></p>
<p>â€” <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.
                                    <span class="Bold">Hemic and Lymphatic System</span><span class="Italics">Infrequent:</span></p>
<p>â€” alkaline phosphatase increased, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">bilirubinemia</span>, <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span>.
                                    <span class="Bold">Metabolic and Nutritional Disorders</span><span class="Italics">Infrequent:</span></p>
<p>â€” <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>.
                                    <span class="Bold">Musculoskeletal System</span><span class="Italics">Rare:</span></p>
<p>â€” <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">libido decreased</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>; <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.
                                    <span class="Bold">Nervous System</span><span class="Italics">Infrequent:</span><span class="Italics">Rare:</span></p>
<p>â€” <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>; <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">lung edema</span>.
                                    <span class="Bold">Respiratory System</span><span class="Italics">Infrequent:</span><span class="Italics">Rare:</span></p>
<p>â€” <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>.
                                    <span class="Bold">Skin and Appendages</span><span class="Italics">Infrequent:</span></p>
<p>â€” <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">abnormality of accommodation</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>; <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>.
                                    <span class="Bold">Special Senses</span><span class="Italics">Infrequent:</span><span class="Italics">Rare:</span></p>
<p>â€” <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> , <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, decreased menstruation, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> , increased menstruation , <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">menorrhagia</span> , <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span> , <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> , <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="200845" conceptname="Urgent desire to urinate">urinary urgency</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">urination impaired</span>.
                                    <span class="Bold">Urogenital System</span><span class="Italics">Infrequent:</span><span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span></p>
<p>These terms represent serious adverse events but do not meet the definition for adverse drug reactions. They are included here because of their seriousness.
                                    <span class="Sup">1</span></p>
<p>Adjusted for gender.
                                    <span class="Sup">2</span></p>
<p><span class="Bold"><span class="Italics">Other Adverse Reactions Observed During the Clinical Trial Evaluation of Intramuscular Olanzapine for Injection</span></span></p>
<p>Following is a list of treatment-emergent adverse reactions reported by patients treated with intramuscular Olanzapine for Injection (at 1 or more doses â‰¥2.5 mg/injection) in clinical trials. This listing is not intended to include reactions (1) already listed in previous tables or elsewhere in labeling, (2) for which a drug cause was remote, (3) which were so general as to be uninformative, (4) which were not considered to have significant clinical implications, or (5) for which occurred at a rate equal to or less than placebo. Reactions are classified by body system using the following definitions: frequent adverse reactions are those occurring in at least 1/100 patients; infrequent adverse reactions are those occurring in 1/100 to 1/1000 patients.</p>
<p>â€” <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span>.
                                    <span class="Bold">Body as a Whole</span><span class="Italics">Frequent:</span></p>
<p>â€” <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.
                                    <span class="Bold">Cardiovascular System</span><span class="Italics">Infrequent:</span></p>
<p>â€” <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.
                                    <span class="Bold">Digestive System</span><span class="Italics">Infrequent:</span></p>
<p>â€” creatine phosphokinase increased.
                                    <span class="Bold">Metabolic and Nutritional Disorders</span><span class="Italics">Infrequent:</span></p>
<p><span class="Bold"><span class="Italics">Clinical Trials in Adolescent Patients (age 13 to 17 years)</span></span></p>
<p><span class="Italics">Commonly Observed Adverse Reactions in Oral Olanzapine Short-Term, Placebo-Controlled Trials</span></p>
<p>Adverse reactions in adolescent patients treated with oral olanzapine (doses â‰¥2.5 mg) reported with an incidence of 5% or more and reported at least twice as frequently as placebo-treated patients are listed in .
                                    <span class="Bold">Table 21</span></p>
<p><span class="Bold">Table 21: Treatment-Emergent Adverse Reactions of â‰¥5% Incidence among Adolescents (13 to 17 Years Old) with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> or Mixed Episodes)</span></p>
<a name="id_97708613-9922-49f6-adb1-edf8518bfd21"></a><table border="single" width="490">
<col width="20.4%">
<col width="20.2%">
<col width="20.2%">
<col width="19.9%">
<col width="19.3%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="3" valign="top">
<p class="First"><span class="Bold">Adverse Reactions</span></p>
<span class="Bold">Adverse  Reactions</span>
</td>
<td class="Botrule Rrule" align="center" colspan="4" valign="top"><span class="Bold">Percentage of Patients Reporting Event</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">6 Week Trial % <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> Patients</span></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">3 Week Trial % Bipolar Patients</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Olanzapine</span></p>
<span class="Bold">(N=72)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<span class="Bold">(N=35)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Olanzapine</span></p>
<span class="Bold">(N=107)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<span class="Bold">(N=54)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Sedation
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">39</td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
<td class="Botrule Rrule" align="center" valign="top">48</td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight increased</span></td>
<td class="Botrule Rrule" align="center" valign="top">31</td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
<td class="Botrule Rrule" align="center" valign="top">29</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Rrule" align="center" valign="top">17</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">17</td>
<td class="Botrule Rrule" align="center" valign="top">17</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span></td>
<td class="Botrule Rrule" align="center" valign="top">17</td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
<td class="Botrule Rrule" align="center" valign="top">29</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>
                                                <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">14</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Rrule" align="center" valign="top">4</td>
<td class="Rrule" align="center" valign="top">0</td>
<td class="Rrule" align="center" valign="top">7</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
</tbody>
</table>
<p>Patients with the following MedDRA terms were counted in this category: <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">hypersomnia</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, sedation, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.
                                    <span class="Sup">a</span></p>
<p>Patients with the following MedDRA terms were counted in this category: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="193322" conceptname="Right lower quadrant pain">abdominal pain lower</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>.
                                    <span class="Sup">b</span></p>
<p><span class="Italics">Adverse Reactions Occurring at an Incidence of 2% or More among Oral Olanzapine-Treated Patients in Short-Term (3 to 6</span><span class="Italics">weeks), Placebo-Controlled Trials</span></p>
<p>Adverse reactions in adolescent patients treated with oral olanzapine (doses â‰¥2.5 mg) reported with an incidence of 2% or more and greater than placebo are listed in .
                                    <span class="Bold">Table 22</span></p>
<p>â‰¥
                                    <span class="Bold">Table 22: Treatment-Emergent Adverse Reactions of</span><span class="Bold">2% Incidence among Adolescents (13 to 17 Years Old) (Combined Incidence from Short-Term, Placebo-Controlled Clinical Trials of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span><span class="Bold">or <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> [<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> or Mixed Episodes])</span></p>
<a name="id_e490091d-a051-4aca-b96c-dbde4cbb6027"></a><table border="single" width="416">
<col width="43.2%">
<col width="44.2%">
<col width="12.5%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top"><p class="First"><span class="Bold">Percentage of Patients Reporting Event</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Olanzapine</span></p>
<span class="Bold">(N=179)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<span class="Bold">(N=89)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Sedation
                                                <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">44</td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight increased</span></td>
<td class="Botrule Rrule" align="center" valign="top">30</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span></td>
<td class="Botrule Rrule" align="center" valign="top">24</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Rrule" align="center" valign="top">17</td>
<td class="Botrule Rrule" align="center" valign="top">12</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Liver enzymes increased
                                                <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infection</span>
                                                <span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">Musculoskeletal stiffness</span></td>
<td class="Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
</tbody>
</table>
<p>Patients with the following MedDRA terms were counted in this category: <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">hypersomnia</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, sedation, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.
                                    <span class="Sup">a</span></p>
<p>The terms <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT), <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (AST), and hepatic enzyme were combined under liver enzymes.
                                    <span class="Sup">b</span></p>
<p>Patients with the following MedDRA terms were counted in this category: <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infection</span> viral, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4085100" conceptname="Viral upper respiratory tract infection">viral upper respiratory tract infection</span>.
                                    <span class="Sup">c</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1138b2cb-cba5-423d-899d-f7d6def5f8d1"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Vital Signs and Laboratory Studies</h2>
<p class="First"><span class="Bold"><span class="Italics">Vital Sign Changes</span></span></p>
<p>Oral olanzapine was associated with <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> in clinical trials. Intramuscular olanzapine for injection was associated with <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> in clinical trials .
                                    <span class="Italics">[see Â </span><span class="Bold">WARNINGS AND PRECAUTIONS ( )
                                        <a href="#i4i_warnings_precautions_id_6042a0c1-04b0-4c54-9216-943b8a69d0b3">5</a></span><span class="Italics">]</span></p>
<p><span class="Bold"><span class="Italics">Laboratory Changes</span></span></p>
<p>An assessment of the premarketing experience for olanzapine revealed an association with asymptomatic increases in ALT, AST, and GGT. Within the original premarketing database of about 2400 adult patients with  baseline ALT â‰¤90 IU/L, the incidence of ALT elevations to &gt;200 IU/L was 2% (50/2381). None of these patients experienced <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or other symptoms attributable to liver impairment and most had transient changes that tended to normalize while olanzapine treatment was continued.
                                    <span class="Italics">Olanzapine Monotherapy in Adults:</span></p>
<p>In placebo-controlled olanzapine monotherapy studies in adults, clinically significant ALT elevations (change from &lt;3 times the upper limit of normal [ULN] at baseline to â‰¥3 times ULN) were observed in 5% (77/1426) of patients exposed to olanzapine compared to 1% (10/1187) of patients exposed to placebo. ALT elevations â‰¥5 times ULN were observed in 2% (29/1438) of olanzapine-treated patients, compared to 0.3% (4/1196) of placebo-treated patients. ALT values returned to normal, or were decreasing, at last follow-up in the majority of patients who either continued treatment with olanzapine or discontinued olanzapine. No patient with elevated ALT values experienced <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>, or met the criteria for Hyâ€™s Rule.</p>
<p>Rare postmarketing reports of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> have been received. Very rare cases of cholestatic or mixed <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> have also been reported in the postmarketing period.</p>
<p>Caution should be exercised in patients with signs and symptoms of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, in patients with pre-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic drugs.</p>
<p>Olanzapine administration was also associated with increases in serum prolactin , with an asymptomatic elevation of the eosinophil count in 0.3% of patients, and with an increase in CPK.
                                    <span class="Italics">[see Â </span><span class="Bold">WARNINGS AND PRECAUTIONS ( )
                                        <a href="#i4i_section_id_e0108bdd-04bd-4fa7-8193-61c0a08c3b15">5.15</a></span><span class="Italics">]</span></p>
<p>In placebo-controlled clinical trials of adolescent patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes), greater frequencies for the following treatment-emergent findings, at anytime, were observed in laboratory analytes compared to placebo: elevated ALT (â‰¥3X ULN in patients with ALT at baseline &lt;3X ULN), (12% vs 2%); elevated AST (28% vs 4%); low total bilirubin (22% vs 7%); elevated GGT (10% vs 1%); and elevated prolactin (47% vs 7%).
                                    <span class="Bold"><span class="Italics">Olanzapine Monotherapy in Adolescents</span></span><span class="Italics">:</span></p>
<p>In placebo-controlled olanzapine monotherapy studies in adolescents, clinically significant ALT elevations (change from &lt;3 times ULN at baseline to â‰¥3 times ULN) were observed in 12% (22/192) of patients exposed to olanzapine compared to 2% (2/109) of patients exposed to placebo. ALT elevations â‰¥5 times ULN were observed in 4% (8/192) of olanzapine-treated patients, compared to 1% (1/109) of placebo-treated patients. ALT values returned to normal, or were decreasing, at last follow-up in the majority of patients who either continued treatment with olanzapine or discontinued olanzapine. No adolescent patient with elevated ALT values experienced <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>, or met the criteria for Hyâ€™s Rule.</p>
<p><span class="Bold"><span class="Italics">ECG Changes</span></span></p>
<p>In pooled studies of adults as well as pooled studies of adolescents, there were no significant differences between olanzapine and placebo in the proportions of patients experiencing potentially important changes in ECG parameters, including QT, QTc (Fridericia corrected), and PR intervals. Olanzapine use was associated with a mean increase in heart rate compared to placebo (adults: +2.4 beats per minute vs no change with placebo; adolescents: +6.3 beats per minute vs -5.1 beats per minute with placebo). This increase in heart rate may be related to olanzapineâ€™s potential for inducing orthostatic changes .
                                    <span class="Italics">[see</span><span class="Bold">WARNINGS AND PRECAUTIONS ( )
                                        <a href="#i4i_section_id_21fd3f46-acca-42c1-b2b9-21545674f9f4">5.8</a></span><span class="Italics">]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_94e0a841-3c0e-40cd-9f1e-0c0364b2bd7b"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of Olanzapine for Injection. Because these reactions are reported voluntarily from a population of uncertain size, it is difficult to reliably estimate their frequency or evaluate a causal relationship to drug exposure.</p>
<p>Adverse reactions reported since market introduction that were temporally (but not necessarily causally) related to Olanzapine for Injection therapy include the following: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> or <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>), <span class="product-label-link" type="condition" conceptid="4095288" conceptname="Diabetic coma with ketoacidosis">diabetic coma</span>, <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>, discontinuation reaction (<span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>), <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, and venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> (including <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> and deep <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>). Random <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels of â‰¥240 mg/dL and random triglyceride levels of â‰¥1000 mg/dL have been reported.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_59a2af3d-f786-459e-84d4-02bc8ff712f1"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a12a79d5-56a9-4ea2-916f-d8d6d2cf77e3"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Potential for Other Drugs to Affect Olanzapine</h2>
<p class="First"><span class="Bold"><span class="Italics">Diazepam</span></span></p>
<p>The co-administration of diazepam with olanzapine potentiated the <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> observed with olanzapine .
                                    <span class="Italics">[see Â </span><span class="Bold">DRUG INTERACTIONS ( )
                                        <a href="#i4i_section_id_5d447741-a374-4a00-9b8e-59fcfe820661">7.2</a></span><span class="Italics">]</span></p>
<p><span class="Bold"><span class="Italics">Cimetidine and Antacids</span></span></p>
<p>Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.</p>
<p><span class="Bold"><span class="Italics">Inducers of CYP1A2</span></span></p>
<p>Carbamazepine therapy (200 mg bid) causes an approximately 50% increase in the clearance of olanzapine. This increase is likely due to the fact that carbamazepine is a potent inducer of CYP1A2 activity. Higher daily doses of carbamazepine may cause an even greater increase in olanzapine clearance.</p>
<p><span class="Bold"><span class="Italics">Alcohol</span></span></p>
<p>Ethanol (45 mg/70 kg single dose) did not have an effect on olanzapine pharmacokinetics. The co-administration of alcohol (i.e., ethanol) with olanzapine potentiated the <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> observed with olanzapine .
                                    <span class="Italics">[seeÂ </span><span class="Bold">DRUG INTERACTIONS ( )
                                        <a href="#i4i_section_id_5d447741-a374-4a00-9b8e-59fcfe820661">7.2</a></span><span class="Italics">]</span></p>
<p><span class="Bold"><span class="Italics">Inhibitors of CYP1A2</span></span></p>
<p>Fluvoxamine, a CYP1A2 inhibitor, decreases the clearance of olanzapine. This results in a mean increase in olanzapine C following fluvoxamine of 54% in female <span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">nonsmokers</span> and 77% in male smokers. The mean increase in olanzapine AUC is 52% and 108%, respectively. Lower doses of olanzapine should be considered in patients receiving concomitant treatment with fluvoxamine.
                                    <span class="Italics">Fluvoxamine:</span><span class="Sub">max</span></p>
<p><span class="Bold"><span class="Italics">Warfarin</span></span></p>
<p>Warfarin (20 mg single dose) did not affect olanzapine pharmacokinetics .
                                    <span class="Italics">[see Â </span><span class="Bold">DRUG INTERACTIONS ( )
                                        <a href="#i4i_section_id_5d447741-a374-4a00-9b8e-59fcfe820661">7.2</a></span><span class="Italics">]</span></p>
<p><span class="Bold"><span class="Italics">Inducers of CYP1A2 or Glucuronyl Transferase</span></span></p>
<p>Omeprazole and rifampin may cause an increase in olanzapine clearance.</p>
<p><span class="Bold"><span class="Italics">Charcoal</span></span></p>
<p>The administration of activated charcoal (1 g) reduced the C and AUC of oral olanzapine by about 60%. As peak olanzapine levels are not typically obtained until about 6 hours after dosing, charcoal may be a useful treatment for olanzapine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.
                                    <span class="Sub">max</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5d447741-a374-4a00-9b8e-59fcfe820661"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Potential for Olanzapine to Affect Other Drugs</h2>
<p class="First"><span class="Bold"><span class="Italics">CNS Acting Drugs</span></span></p>
<p>Given the primary CNS effects of olanzapine, caution should be used when olanzapine is taken in combination with other centrally acting drugs and alcohol.</p>
<p><span class="Bold"><span class="Italics">Antihypertensive Agents</span></span></p>
<p>Olanzapine, because of its potential for inducing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, may enhance the effects of certain antihypertensive agents.</p>
<p><span class="Bold"><span class="Italics">Levodopa and Dopamine Agonists</span></span></p>
<p>Olanzapine may antagonize the effects of levodopa and dopamine agonists.</p>
<p><span class="Bold"><span class="Italics">Lorazepam (IM)</span></span></p>
<p>Administration of intramuscular lorazepam (2 mg) 1 hour after intramuscular Olanzapine for Injection (5 mg) did not significantly affect the pharmacokinetics of olanzapine, unconjugated lorazepam, or total lorazepam. However, this co-administration of intramuscular lorazepam and intramuscular Olanzapine for Injection added to the <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> observed with either drug alone .
                                    <span class="Italics">[see Â </span><span class="Bold">WARNINGS AND PRECAUTIONS ( )
                                        <a href="#i4i_section_id_21fd3f46-acca-42c1-b2b9-21545674f9f4">5.8</a></span><span class="Italics">]</span></p>
<p><span class="Bold"><span class="Italics">Lithium</span></span></p>
<p>Multiple doses of olanzapine (10 mg for 8 days) did not influence the kinetics of lithium. Therefore, concomitant olanzapine administration does not require dosage adjustment of lithium .
                                    <span class="Italics">[see</span><span class="Bold">WARNINGS AND PRECAUTIONS ( )
                                        <a href="#i4i_section_id_13de78d4-a97d-4881-b8d2-474d5cd0832f">5.16</a></span><span class="Italics">]</span></p>
<p><span class="Bold"><span class="Italics">Valproate</span></span></p>
<p>Olanzapine (10 mg daily for 2 weeks) did not affect the steady state plasma concentrations of valproate. Therefore, concomitant olanzapine administration does not require dosage adjustment of valproate. .
                                    <span class="Italics">[see Â </span><span class="Bold">WARNINGS AND PRECAUTIONS ( )
                                        <a href="#i4i_section_id_13de78d4-a97d-4881-b8d2-474d5cd0832f">5.16</a></span><span class="Italics">]</span></p>
<p><span class="Bold"><span class="Italics">Effect of Olanzapine on Drug Metabolizing Enzymes</span></span></p>
<p>studies utilizing human liver microsomes suggest that olanzapine has little potential to inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A. Thus, olanzapine is unlikely to cause clinically important drug interactions mediated by these enzymes.
                                    <span class="Italics">In vitro</span></p>
<p><span class="Bold"><span class="Italics">Imipramine</span></span></p>
<p>Single doses of olanzapine did not affect the pharmacokinetics of imipramine or its active metabolite desipramine.</p>
<p><span class="Bold"><span class="Italics">Warfarin</span></span></p>
<p>Single doses of olanzapine did not affect the pharmacokinetics of warfarin .
                                    <span class="Italics">[see Â </span><span class="Bold">DRUG INTERACTIONS ( )
                                        <a href="#i4i_section_id_a12a79d5-56a9-4ea2-916f-d8d6d2cf77e3">7.1</a></span><span class="Italics">]</span></p>
<p><span class="Bold"><span class="Italics">Diazepam</span></span></p>
<p>Olanzapine did not influence the pharmacokinetics of diazepam or its active metabolite N-desmethyldiazepam. However, diazepam co-administered with olanzapine increased the <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> observed with either drug given alone .
                                    <span class="Italics">[see Â </span><span class="Bold">DRUG INTERACTIONS ( )
                                        <a href="#i4i_section_id_a12a79d5-56a9-4ea2-916f-d8d6d2cf77e3">7.1</a></span><span class="Italics">]</span></p>
<p><span class="Bold"><span class="Italics">Alcohol</span></span></p>
<p>Multiple doses of olanzapine did not influence the kinetics of ethanol .
                                    <span class="Italics">[see Â </span><span class="Bold">DRUG INTERACTIONS (7.1)</span><span class="Italics">]</span></p>
<p><span class="Bold"><span class="Italics">Biperiden</span></span></p>
<p>Multiple doses of olanzapine did not influence the kinetics of biperiden.</p>
<p><span class="Bold"><span class="Italics">Theophylline</span></span></p>
<p>Multiple doses of olanzapine did not affect the pharmacokinetics of theophylline or its metabolites.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_f3a4c8cc-e9ed-43d2-99a2-08c493021fee"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_d0d32cab-bdd8-4428-a965-7fcc395578f7"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold"><span class="Italics">Teratogenic Effects, Pregnancy Category C</span></span></p>
<p>In oral reproduction studies in rats at doses up to 18 mg/kg/day and in rabbits at doses up to 30 mg/kg/day (9 and 30 times the maximum recommended human daily oral dose on a mg/m basis, respectively) no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was observed. In an oral rat teratology study, early resorptions and increased numbers of nonviable fetuses were observed at a dose of 18 mg/kg/day (9 times the maximum recommended human daily oral dose on a mg/m basis). Gestation was prolonged at 10 mg/kg/day (5 times the maximum recommended human daily oral dose on a mg/m basis). In an oral rabbit teratology study, fetal toxicity (manifested as increased resorptions and decreased fetal weight) occurred at a maternally toxic dose of 30 mg/kg/day (30 times the maximum recommended human daily oral dose on a mg/m basis). Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
                                    <span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span></p>
<p>Placental transfer of olanzapine occurs in rat pups.</p>
<p>There are no adequate and well-controlled trials with olanzapine in pregnant females. Seven pregnancies were observed during clinical trials with olanzapine, including 2 resulting in normal births, 1 resulting in neonatal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to a cardiovascular defect, 3 therapeutic abortions, and 1 <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span>.</p>
<p><span class="Bold"><span class="Italics">Non-Teratogenic Effects</span></span></p>
<p>Neonates exposed to antipsychotic drugs (including Olanzapine for Injection), during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> and <span class="product-label-link" type="condition" conceptid="434750" conceptname="Feeding difficulties and mismanagement">feeding disorder</span> in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization.</p>
<p>Olanzapine for Injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_6ee9e171-85e1-4246-840c-bd4be76d8905"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">The effect of olanzapine on labor and delivery in humans is unknown. Parturition in rats was not affected by olanzapine.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_4707cef8-0542-4f74-b407-6607a781f6f1"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">In a study in lactating, healthy women, olanzapine was excreted in breast milk. Mean infant dose at steady state was estimated to be 1.8% of the maternal olanzapine dose. It is recommended that women receiving olanzapine should not breast-feed.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_4ad67cbe-6947-4393-9bb2-37fdbf3742c9"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Compared to patients from adult clinical trials, adolescents were likely to gain more weight, experience increased sedation, and have greater increases in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, triglycerides, LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, prolactin and hepatic aminotransferase levels AND . When deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>. Clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents.
                                    <span class="Italics">[see Â </span><span class="Bold">WARNINGS AND PRECAUTIONS ( , , , )
                                        <a href="#i4i_section_id_124564fe-51e9-46ca-a1ce-7dc43aa9fb93">5.5</a><a href="#i4i_section_id_5769fed0-eeeb-40f7-b036-881654461749">5.6</a><a href="#i4i_section_id_e0108bdd-04bd-4fa7-8193-61c0a08c3b15">5.15</a><a href="#i4i_section_id_393e8125-cf30-4c4c-9b49-181c837755c4">5.17</a></span><span class="Bold">ADVERSE REACTIONS ( )
                                        <a href="#i4i_section_id_1138b2cb-cba5-423d-899d-f7d6def5f8d1">6.2</a></span><span class="Italics">]</span></p>
<p>Safety and effectiveness of olanzapine for injection in children &lt;18 years of age have not been established .
                                    <span class="Italics">[see Â </span><span class="Bold">PATIENT COUNSELING INFORMATION ( )
                                        <a href="#i4i_section_id_d16f7c18-8711-43c0-81dc-339beb51c65a">17.13</a></span><span class="Italics">]</span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_66add21b-88d4-434c-bdb6-8bfcb0296fe9"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Studies in elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> have suggested that there may be a different tolerability profile in this population compared to younger patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with olanzapine are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> compared to placebo. In placebo-controlled studies of olanzapine in elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, there was a higher incidence of cerebrovascular adverse events (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack) in patients treated with olanzapine compared to patients treated with placebo. Olanzapine is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. Also, the presence of factors that might decrease pharmacokinetic clearance or increase the pharmacodynamic response to olanzapine should lead to consideration of a lower starting dose for any geriatric patient AND .
                                    <span class="Italics">[see Â </span><span class="Bold">BOXED WARNING</span><span class="Bold">WARNINGS AND PRECAUTIONS ( )
                                        <a href="#i4i_section_id_617516a7-e25b-4b1e-8645-61d3c78a63d5">5.1</a></span><span class="Italics">]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="i4i_abuse_dependence_id_ca923a81-af75-4fcf-9f2f-110d7efc8852"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34087-7">
<a name="i4i_dependence_id_d639463f-12d1-4816-b2c5-31c9094f17d0"></a><a name="section-9.1"></a><p></p>
<h2>9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">In studies prospectively designed to assess abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> potential, olanzapine was shown to have acute depressive CNS effects but little or no potential of abuse or physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> in rats administered oral doses up to 15 times the maximum recommended human daily oral dose (20 mg) and rhesus monkeys administered oral doses up to 8 times the maximum recommended human daily oral dose on a mg/m basis.
                                    <span class="Sup">2</span></p>
<p>Olanzapine has not been systematically studied in humans for its potential for abuse, tolerance, or physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. While the clinical trials did not reveal any tendency for any drug-seeking behavior, these observations were not systematic, and it is not possible to predict on the basis of this limited experience the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, patients should be evaluated carefully for a history of drug abuse, and such patients should be observed closely for signs of misuse or abuse of olanzapine (e.g., development of tolerance, increases in dose, drug-seeking behavior).</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_a33aaa89-2ce3-4ae3-b442-1c6d4cdbed4c"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0b636bc5-48e5-43f2-97f8-e67fe9e6b9d1"></a><a name="section-10.1"></a><p></p>
<h2>10.1 Human Experience</h2>
<p class="First">In premarketing trials involving more than 3100 patients and/or normal subjects, accidental or intentional acute overdosage of olanzapine was identified in 67 patients. In the patient taking the largest identified amount, 300 mg, the only symptoms reported were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>. In the limited number of patients who were evaluated in hospitals, including the patient taking 300 mg, there were no observations indicating an adverse change in laboratory analytes or ECG. Vital signs were usually within normal limits following <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>.</p>
<p>In postmarketing reports of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with olanzapine alone, symptoms have been reported in the majority of cases. In symptomatic patients, symptoms with â‰¥10% incidence included <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>/<span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, various <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, and reduced level of consciousness ranging from sedation to <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. Among less commonly reported symptoms were the following potentially medically serious reactions: <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>, <span class="product-label-link" type="condition" conceptid="4256374" conceptname="Cardiorespiratory arrest">cardiopulmonary arrest</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> (such as <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span> and 1 patient experiencing sinus pause with spontaneous resumption of normal rhythm), <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, possible <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>/arrest, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. Company has received reports of fatality in association with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of olanzapine alone. In 1 case of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, the amount of acutely ingested olanzapine was reported to be possibly as low as 450 mg of oral olanzapine; however, in another case, a patient was reported to survive an acute olanzapine ingestion of approximately 2 g of oral olanzapine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6ba5886d-3958-4343-b94c-8ef59273cd89"></a><a name="section-10.2"></a><p></p>
<h2>10.2 Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></h2>
<p class="First">The possibility of multiple drug involvement should be considered. In case of acute overdosage, establish and maintain an airway and ensure adequate oxygenation and ventilation, which may include intubation. Gastric lavage (after intubation, if patient is <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconscious</span>) and administration of activated charcoal together with a laxative should be considered. The administration of activated charcoal (1 g) reduced the C and AUC of oral olanzapine by about 60%. As peak olanzapine levels are not typically obtained until about 6 hours after dosing, charcoal may be a useful treatment for olanzapine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.
                                    <span class="Sub">max</span></p>
<p>The possibility of <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">obtundation</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, or <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reaction</span> of the head and neck following <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may create a risk of <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> with induced <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>. Cardiovascular monitoring should commence immediately and should include continuous electrocardiographic monitoring to detect possible <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>.</p>
<p>There is no specific antidote to olanzapine. Therefore, appropriate supportive measures should be initiated. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span> should be treated with appropriate measures such as intravenous fluids and/or sympathomimetic agents. (Do not use epinephrine, dopamine, or other sympathomimetics with beta-agonist activity, since beta stimulation may worsen <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in the setting of olanzapine-induced alpha blockade.) Close medical supervision and monitoring should continue until the patient recovers.</p>
<p>For specific information about overdosage with lithium or valproate, refer to the overdosage section of the package inserts for these products.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_ae3a331d-db12-4067-8709-f6b0d1951b6f"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Olanzapine is an atypical antipsychotic that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-(4-methyl-1-piperazinyl)-10 -thieno[2,3- ] [1,5]benzodiazepine. The molecular formula is C H N S, which corresponds to a molecular weight of 312.44. The chemical structure is:
                            <span class="Italics">H</span><span class="Italics">b</span><span class="Sub">17</span><span class="Sub">20</span><span class="Sub">4</span></p>
<div class="Figure"><img alt="Structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b3bc948-161e-49ee-b67f-4bbb63af23d6&amp;name=1e9666ef-4271-4834-8496-ccb3125d83db-01.jpg"></div>
<p>Olanzapine is a yellow crystalline solid, which is practically insoluble in water.</p>
<p>Olanzapine for Injection is intended for intramuscular use only.</p>
<p>Each vial provides for the administration of 10 mg (32 Î¼mol) olanzapine with inactive ingredients 50 mg lactose monohydrate and 3.5 mg tartaric acid. Hydrochloric acid and/or sodium hydroxide may have been added during manufacturing to adjust pH.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_2a0b6745-056d-4e9a-8272-0198fe6a65d4"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_e6d3a434-90f6-416e-9d6a-7033269628c8"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The mechanism of action of olanzapine, as with other drugs having efficacy in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, is unknown. However, it has been proposed that this drug's efficacy in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> is mediated through a combination of dopamine and serotonin type 2 (5HT ) antagonism. The mechanism of action of olanzapine in the treatment of acute <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> is unknown.
                                    <span class="Sub">2</span></p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_ba56240c-1772-4b16-9faf-a4928a9b298a"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Olanzapine binds with high affinity to the following receptors: serotonin 5HT , 5HT (K =4, 11, and 5 nM, respectively), dopamine D (K =11-31 nM), histamineÂ H (K =7 nM), and adrenergic Î± receptors (K =19 nM). Olanzapine is an antagonist with moderate affinity binding for serotonin 5HT (K =57 nM) and muscarinic M (K =73, 96, 132, 32, and 48 nM, respectively). Olanzapine binds weakly to GABA , BZD, and Î²-adrenergic receptors (K &gt;10 Î¼M).
                                    <span class="Sub">2A/2C</span><span class="Sub">6</span><span class="Sub">i</span><span class="Sub">1-4</span><span class="Sub">i</span><span class="Sub">1</span><span class="Sub">i</span><span class="Sub">1</span><span class="Sub">i</span><span class="Sub">3</span><span class="Sub">i</span><span class="Sub">1-5</span><span class="Sub">i</span><span class="Sub">A</span><span class="Sub">i</span></p>
<p>Antagonism at receptors other than dopamine and 5HT may explain some of the other therapeutic and side effects of olanzapine. Olanzapine's antagonism of muscarinic M receptors may explain its anticholinergic-like effects. Olanzapine's antagonism of histamine H receptors may explain the <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> observed with this drug. Olanzapine's antagonism of adrenergic Î± receptors may explain the <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> observed with this drug.
                                    <span class="Sub">2</span><span class="Sub">1-5</span><span class="Sub">1</span><span class="Sub">1</span></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_b00c26eb-c1dd-4dc2-912e-49ce4c3d3ecd"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Bold">Â </span><span class="Bold"><span class="Italics">Oral Administration, Monotherapy</span></span></p>
<p>Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose. It is eliminated extensively by first pass metabolism, with approximately 40% of the dose metabolized before reaching the systemic circulation. Food does not affect the rate or extent of olanzapine absorption. Pharmacokinetic studies showed that olanzapine tablets and olanzapine orally disintegrating tablets dosage forms of olanzapine are bioequivalent.</p>
<p>Olanzapine displays linear kinetics over the clinical dosing range. Its half-life ranges from 21 to 54 hours (5th to 95th percentile; mean of 30 hr), and apparent plasma clearance ranges from 12 to 47 L/hr (5th to 95th percentile; mean of 25 L/hr).</p>
<p>Administration of olanzapine once daily leads to steady-state concentrations in about 1 week that are approximately twice the concentrations after single doses. Plasma concentrations, half-life, and clearance of olanzapine may vary between individuals on the basis of smoking status, gender, and age.</p>
<p>Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L. It is 93% bound to plasma proteins over the concentration range of 7 to 1100 ng/mL, binding primarily to albumin and Î± -acid glycoprotein.
                                    <span class="Sub">1</span></p>
<p><span class="Bold"><span class="Italics">Metabolism and Elimination</span></span></p>
<p>Following a single oral dose of C labeled olanzapine, 7% of the dose of olanzapine was recovered in the urine as unchanged drug, indicating that olanzapine is highly metabolized. Approximately 57% and 30% of the dose was recovered in the urine and feces, respectively. In the plasma, olanzapine accounted for only 12% of the AUC for total radioactivity, indicating significant exposure to metabolites. After multiple dosing, the major circulating metabolites were the 10-N-glucuronide, present at steady state at 44% of the concentration of olanzapine, and 4Â´-N-desmethyl olanzapine, present at steady state at 31% of the concentration of olanzapine. Both metabolites lack pharmacological activity at the concentrations observed.
                                    <span class="Sup">14</span></p>
<p>Direct glucuronidation and cytochrome P450 (CYP) mediated oxidation are the primary metabolic pathways for olanzapine. studies suggest that CYPs 1A2 and 2D6, and the flavin-containing monooxygenase system are involved in olanzapine oxidation. CYP2D6 mediated oxidation appears to be a minor metabolic pathway , because the clearance of olanzapine is not reduced in subjects who are deficient in this enzyme
                                    <span class="Italics">In vitro</span><span class="Italics">in vivo</span></p>
<p><span class="Bold"><span class="Italics">Intramuscular Administration</span></span></p>
<p>Olanzapine for Injection results in rapid absorption with peak plasma concentrations occurring within 15 to 45 minutes. Based upon a pharmacokinetic study in healthy volunteers, a 5 mg dose of intramuscular Olanzapine for Injection produces, on average, a maximum plasma concentration approximately 5 times higher than the maximum plasma concentration produced by a 5 mg dose of oral olanzapine. Area under the curve achieved after an intramuscular dose is similar to that achieved after oral administration of the same dose. The half-life observed after intramuscular administration is similar to that observed after oral dosing. The pharmacokinetics are linear over the clinical dosing range. Metabolic profiles after intramuscular administration are qualitatively similar to metabolic profiles after oral administration.</p>
<p><span class="Bold"><span class="Italics">Specific Populations</span></span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>Because olanzapine is highly metabolized before excretion and only 7% of the drug is excreted unchanged, renal dysfunction alone is unlikely to have a major impact on the pharmacokinetics of olanzapine. The pharmacokinetic characteristics of olanzapine were similar in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and normal subjects, indicating that dosage adjustment based upon the degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not required. In addition, olanzapine is not removed by dialysis. The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on metabolite elimination has not been studied.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>Although the presence of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> may be expected to reduce the clearance of olanzapine, a study of the effect of <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span> in subjects (n=6) with clinically significant (Childs Pugh Classification A and B) cirrhosis revealed little effect on the pharmacokinetics of olanzapine.</p>
<p><span class="Italics">Geriatric</span></p>
<p>In a study involving 24 healthy subjects, the mean elimination half-life of olanzapine was about 1.5 times greater in elderly (â‰¥65 years) than in nonelderly subjects (&lt;65 years). Caution should be used in dosing the elderly, especially if there are other factors that might additively influence drug metabolism and/or pharmacodynamic sensitivity .
                                    <span class="Italics">[see Â </span><span class="Bold">DOSAGE AND ADMINISTRATION ( )
                                        <a href="#i4i_dosage_admin_id_3cf5f9c6-270f-42d9-ba13-7b3f9a5607dc">2</a></span><span class="Italics">]</span></p>
<p><span class="Italics">Gender</span></p>
<p>Clearance of olanzapine is approximately 30% lower in women than in men. There were, however, no apparent differences between men and women in effectiveness or adverse effects. Dosage modifications based on gender should not be needed.</p>
<p><span class="Italics">Smoking Status</span></p>
<p>Olanzapine clearance is about 40% higher in smokers than in <span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">nonsmokers</span>, although dosage modifications are not routinely recommended.</p>
<p><span class="Italics">Race</span></p>
<p>studies have shown that exposures are similar among Japanese, Chinese and Caucasians, especially after normalization for body weight differences. Dosage modifications for race are, therefore, not recommended.
                                    <span class="Italics">In vivo</span></p>
<p><span class="Italics">Combined Effects</span></p>
<p>The combined effects of age, smoking, and gender could lead to substantial pharmacokinetic differences in populations. The clearance in young smoking males, for example, may be 3 times higher than that in elderly nonsmoking females. Dosing modification may be necessary in patients who exhibit a combination of factors that may result in slower metabolism of olanzapine .
                                    <span class="Italics">[see Â </span><span class="Bold">DOSAGE AND ADMINISTRATION ( )
                                        <a href="#i4i_dosage_admin_id_3cf5f9c6-270f-42d9-ba13-7b3f9a5607dc">2</a></span><span class="Italics">]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_9ade0352-d489-44ff-9fc2-d131e629465b"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_29c956ff-094b-486e-9f46-5dc48970f1aa"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Bold"><span class="Italics">Carcinogenesis</span></span></p>
<p>Oral carcinogenicity studies were conducted in mice and rats. Olanzapine was administered to mice in two 78-week studies at doses of 3, 10, 30/20 mg/kg/day (equivalent to 0.8 to 5 times the maximum recommended human daily oral dose on a mg/m basis) and 0.25, 2, 8 mg/kg/day (equivalent to 0.06 to 2 times the maximum recommended human daily oral dose on a mg/m basis). Rats were dosed for 2 years at doses of 0.25, 1, 2.5, 4 mg/kg/day (males) and 0.25, 1, 4, 8 mg/kg/day (females) (equivalent to 0.13 to 2 and 0.13 to 4 times the maximum recommended human daily oral dose on a mg/m basis, respectively). The incidence of liver <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span> and <span class="product-label-link" type="condition" conceptid="4297200" conceptname="Angiosarcoma">hemangiosarcomas</span> was significantly increased in 1 mouse study in female mice dosed at 8 mg/kg/day (2 times the maximum recommended human daily oral dose on a mg/m basis). These tumors were not increased in another mouse study in females dosed at 10 or 30/20 mg/kg/day (2 to 5 times the maximum recommended human daily oral dose on a mg/m basis); in this study, there was a high incidence of early mortalities in males of the 30/20 mg/kg/day group. The incidence of mammary gland <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and adenocarcinomas was significantly increased in female mice dosed at â‰¥2 mg/kg/day and in female rats dosed at â‰¥4 mg/kg/day (0.5 and 2 times the maximum recommended human daily oral dose on a mg/m basis, respectively). Antipsychotic drugs have been shown to chronically elevate prolactin levels in rodents. Serum prolactin levels were not measured during the olanzapine carcinogenicity studies; however, measurements during subchronic toxicity studies showed that olanzapine elevated serum prolactin levels up to 4-fold in rats at the same doses used in the carcinogenicity study. An increase in mammary gland neoplasms has been found in rodents after chronic administration of other antipsychotic drugs and is considered to be prolactin mediated. The relevance for human risk of the finding of prolactin mediated endocrine tumors in rodents is unknown .
                                    <span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span><span class="Italics">[see Â </span><span class="Bold">WARNINGS AND PRECAUTIONS ( )
                                        <a href="#i4i_section_id_e0108bdd-04bd-4fa7-8193-61c0a08c3b15">5.15</a></span><span class="Italics">]</span></p>
<p><span class="Bold"><span class="Italics">Mutagenesis</span></span></p>
<p>No evidence of genotoxic potential for olanzapine was found in the Ames reverse mutation test, micronucleus test in mice, the chromosomal aberration test in Chinese hamster ovary cells, unscheduled DNA synthesis test in rat hepatocytes, induction of forward mutation test in mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells, or sister chromatid exchange test in bone marrow of Chinese hamsters.
                                    <span class="Italics">in vivo</span><span class="Italics">in vivo</span></p>
<p><span class="Bold"><span class="Italics">Impairment of Fertility</span></span></p>
<p>In an oral fertility and reproductive performance study in rats, male mating performance, but not fertility, was impaired at a dose of 22.4 mg/kg/day and female fertility was decreased at a dose of 3 mg/kg/day (11 and 1.5 times the maximum recommended human daily oral dose on a mg/m basis, respectively). Discontinuance of olanzapine treatment reversed the effects on male mating performance. In female rats, the precoital period was increased and the mating index reduced at 5 mg/kg/day (2.5 times the maximum recommended human daily oral dose on a mg/m basis). Diestrous was prolonged and estrous delayed at 1.1 mg/kg/day (0.6 times the maximum recommended human daily oral dose on a mg/m basis); therefore olanzapine may produce a delay in ovulation.
                                    <span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span></p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_957ff6f1-b7db-45bc-982e-b39c9be7778a"></a><a name="section-13.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">In animal studies with olanzapine, the principal hematologic findings were reversible peripheral <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span> in individual dogs dosed at 10 mg/kg (17 times the maximum recommended human daily oral dose on a mg/m basis), dose-related decreases in <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> and <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> in mice, and <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span> in rats. A few dogs treated with 10 mg/kg developed reversible <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and/or reversible <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> between 1 and 10 months of treatment. Dose-related decreases in <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> and <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> were seen in mice given doses of 10 mg/kg (equal to 2 times the maximum recommended human daily oral dose on a mg/m basis) in studies of 3 months' duration. Nonspecific <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>, consistent with decreased body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, occurred in rats receiving 22.5 mg/kg (11 times the maximum recommended human daily oral dose on a mg/m basis) for 3 months or 16 mg/kg (8 times the maximum recommended human daily oral dose on a mg/m basis) for 6 or 12 months. No evidence of bone marrow cytotoxicity was found in any of the species examined. Bone marrows were normocellular or hypercellular, indicating that the reductions in circulating blood cells were probably due to peripheral (non-marrow) factors.
                                    <span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_56af3324-1807-41fe-813d-bd8348fb3e74"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d44b2269-6f37-4812-be3e-8301e967a954"></a><a name="section-14.1"></a><p></p>
<h2>14.3 <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span> Associated with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> and Bipolar I <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></h2>
<p class="First">The efficacy of intramuscular Olanzapine for Injection for the treatment of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> was established in 3 short-term (24 hours of IM treatment) placebo-controlled trials in <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> adult inpatients from 2 diagnostic groups: <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolarÂ I disorder (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes). Each of the trials included a single active comparator treatment arm of either haloperidol injection (<span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> studies) or lorazepam injection (bipolar I <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> study). Patients enrolled in the trials needed to be: (1) judged by the clinical investigators as clinically <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> and clinically appropriate candidates for treatment with intramuscular medication, and (2) exhibiting a level of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> that met or exceeded a threshold score of â‰¥14 on the 5 items comprising the Positive and Negative Syndrome Scale (PANSS) Excited Component (i.e., poor impulse control, <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, uncooperativeness and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> items) with at least 1 individual item score â‰¥4 using a 1 to 7 scoring system (1=absent, 4=moderate, 7=extreme). In the studies, the mean baseline PANSS Excited Component score was 18.4, with scores ranging from 13 to 32 (out of a maximum score of 35), thus suggesting predominantly moderate levels of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> with some patients experiencing mild or severe levels of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>. The primary efficacy measure used for assessing <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> signs and symptoms in these trials was the change from baseline in the PANSS Excited Component at 2 hours post-injection. Patients could receive up to 3 injections during the 24 hour IM treatment periods; however, patients could not receive the second injection until after the initial 2 hour period when the primary efficacy measure was assessed. The results of the trials follow:</p>
<p>(1) In a placebo-controlled trial in <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> inpatients meeting DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> (n=270), 4 fixed intramuscular Olanzapine for Injection doses of 2.5 mg, 5 mg, 7.5 mg and 10 mg were evaluated. All doses were statistically superior to placebo on the PANSS Excited Component at 2 hours post-injection. However, the effect was larger and more consistent for the 3 highest doses. There were no significant pairwise differences for the 7.5 and 10Â mg doses over the 5 mg dose.</p>
<p>(2)  In a second placebo-controlled trial in <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> inpatients meeting DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> (n=311), 1 fixed intramuscular Olanzapine for Injection dose of 10Â mg was evaluated. Olanzapine for Injection was statistically superior to placebo on the PANSS Excited Component at 2 hours post-injection.</p>
<p>(3)  In a placebo-controlled trial in <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> inpatients meeting DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> (and currently displaying an acute <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episode with or without <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> features) (n=201), 1 fixed intramuscular Olanzapine for Injection dose of 10 mg was evaluated. Olanzapine for Injection was statistically superior to placebo on the PANSS Excited Component at 2 hours post-injection.</p>
<p>Examination of population subsets (age, race, and gender) did not reveal any differential responsiveness on the basis of these subgroupings.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_ab8534c7-cf90-400e-bf59-65eaf0498389"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">NDC:64725-3159-1 in a VIAL of 10 INJECTION, POWDER, FOR SOLUTIONS</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_66aa79f4-27ea-4232-b7ac-998c0689a824"></a><a name="section-15.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">Olanzapine for Injection is available in:</p>
<p>NDC 0781-3159-72, 10 mg vial (1s)</p>
<p>NDC 0781-3159-95, package of 10 vials</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_061d6378-3e2f-4ccb-845b-8bc231c39eda"></a><a name="section-15.2"></a><p></p>
<h2>16.2 Storage and Handling</h2>
<p class="First">Store Olanzapine for Injection vials (before reconstitution) at controlled room temperature, 20Â° to 25Â°C (68Â° to 77Â°F) [ USP Controlled Room Temperature]. Reconstituted Olanzapine for Injection may be stored at controlled room temperature, 20Â° to 25Â°C (68Â° to 77Â°F) [ USP Controlled Room Temperature] for up to 1 hour if necessary. The USP defines controlled room temperature as a temperature maintained thermostatically that encompasses the usual and customary working environment of 20Â° to 25Â°C (68Â° to 77Â°F); that results in a mean kinetic temperature calculated to be not more than 25Â°C; and that allows for excursions between 15Â° and 30Â°C (59Â° and 86Â°F) that are experienced in pharmacies, hospitals, and warehouses.
                                    <span class="Italics">see</span><span class="Italics">see</span><span class="Italics">Discard any unused portion of reconstituted Olanzapine for Injection</span><span class="Italics">IntraMuscular.</span></p>
<p>Protect Olanzapine for Injection from light, do not freeze.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_83da66d9-7901-4552-afaa-9f4a78f826e0"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking Olanzapine for Injection as monotherapy. If you do not think you are getting better or have any concerns about your condition while taking Olanzapine for Injection, call your doctor.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b438b5c0-6445-4cb2-90b5-734f1d3194ac"></a><a name="section-16.1"></a><p></p>
<h2>17.2 Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span>: Increased Mortality and Cerebrovascular Adverse Events (CVAE), Including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></h2>
<p class="First">Patients and caregivers should be advised that elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Patients and caregivers should be advised that elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with Olanzapine for Injection had a significantly higher incidence of cerebrovascular adverse events (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack) compared with placebo.</p>
<p>Olanzapine for Injection is not approved for elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> AND .
                                    <span class="Italics">[see Â </span><span class="Bold">BOXED WARNING</span><span class="Bold">WARNINGS AND PRECAUTIONS ( )
                                        <a href="#i4i_section_id_617516a7-e25b-4b1e-8645-61d3c78a63d5">5.1</a></span><span class="Italics">]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_29001e4c-fa95-4668-825b-73aaed7888c8"></a><a name="section-16.2"></a><p></p>
<h2>17.3 <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)</h2>
<p class="First">Patients and caregivers should be counseled that a potentially fatal symptom complex sometimes referred to as NMS has been reported in association with administration of antipsychotic drugs, including Olanzapine for Injection. Signs and symptoms of NMS include <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status, and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and cardiac dysrhythmia) .
                                    <span class="Italics">[see Â </span><span class="Bold">WARNINGS AND PRECAUTIONS ( )
                                        <a href="#i4i_section_id_910a9ebd-e38e-41e3-bfb9-99663ed38e3b">5.3</a></span><span class="Italics">]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_67eab0e9-3f5e-48ac-ab86-2a94b1872e60"></a><a name="section-16.3"></a><p></p>
<h2>17.4 <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></h2>
<p class="First">Patients should be advised of the potential risk of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse reactions. Patients should be monitored regularly for worsening of glucose control. Patients who have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> should follow their doctor's instructions about how often to check their blood sugar while taking Olanzapine for Injection .
                                    <span class="Italics">[see Â </span><span class="Bold">WARNINGS AND PRECAUTIONS ( )
                                        <a href="#i4i_section_id_5fc99f10-df4d-4ed4-870e-dfe1f1a64919">5.4</a></span><span class="Italics">]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8e84e0b7-f47c-4c8d-8501-55752474fbed"></a><a name="section-16.4"></a><p></p>
<h2>17.5 <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></h2>
<p class="First">Patients should be counseled that <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> has occurred during treatment with Olanzapine for Injection. Patients should have their lipid profile monitored regularly .
                                    <span class="Italics">[see Â </span><span class="Bold">WARNINGS AND PRECAUTIONS ( )
                                        <a href="#i4i_section_id_124564fe-51e9-46ca-a1ce-7dc43aa9fb93">5.5</a></span><span class="Italics">]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_48d74d43-90c2-4ac8-8cef-8ccf7f915193"></a><a name="section-16.5"></a><p></p>
<h2>17.6 <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></h2>
<p class="First">Patients should be counseled that <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> has occurred during treatment with Olanzapine for Injection. Patients should have their weight monitored regularly .
                                    <span class="Italics">[see Â </span><span class="Bold">WARNINGS AND PRECAUTIONS ( )
                                        <a href="#i4i_section_id_5769fed0-eeeb-40f7-b036-881654461749">5.6</a></span><span class="Italics">]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_11946397-d301-4b92-ac42-20196b8f8503"></a><a name="section-16.6"></a><p></p>
<h2>17.7 <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></h2>
<p class="First">Patients should be advised of the risk of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, especially during the period of initial dose titration and in association with the use of concomitant drugs that may potentiate the orthostatic effect of Olanzapine for Injection, e.g., diazepam or alcohol AND . Patients should be advised to change positions carefully to help prevent <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, and to lie down if they feel dizzy or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, until they feel better. Patients should be advised to call their doctor if they experience any of the following signs and symptoms associated with <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, fast or slow heart beat, or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>.
                                    <span class="Italics">[see Â </span><span class="Bold">WARNINGS AND PRECAUTIONS ( )
                                        <a href="#i4i_section_id_21fd3f46-acca-42c1-b2b9-21545674f9f4">5.8</a></span><span class="Bold">DRUG INTERACTIONS ( )
                                        <a href="#i4i_interactions_id_59a2af3d-f786-459e-84d4-02bc8ff712f1">7</a></span><span class="Italics">]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_343579e0-6b2f-4e57-8374-ec5f4d48bbcd"></a><a name="section-16.7"></a><p></p>
<h2>17.8 Potential for Cognitive and Motor Impairment</h2>
<p class="First">Because Olanzapine for Injection has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that Olanzapine for Injection therapy does not affect them adversely .
                                    <span class="Italics">[see Â </span><span class="Bold">WARNINGS AND PRECAUTIONS ( )
                                        <a href="#i4i_section_id_200dd557-0e78-46b9-b86c-c5e866f649e3">5.12</a></span><span class="Italics">]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4ab3fa87-1a5c-463d-a473-a66f9471ab65"></a><a name="section-16.8"></a><p></p>
<h2>17.9 Body Temperature Regulation</h2>
<p class="First">Patients should be advised regarding appropriate care in avoiding overheating and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>. Patients should be advised to call their doctor right away if they become severely ill and have some or all of these symptoms of <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>: <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> too much or not at all, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, feeling very hot, feeling thirsty, not able to produce urine .
                                    <span class="Italics">[see Â </span><span class="Bold">WARNINGS AND PRECAUTIONS ( )
                                        <a href="#i4i_section_id_b3fa98c0-e7cb-4c65-9f90-ce75f783e08e">5.13</a></span><span class="Italics">]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_16569aec-dc96-42f0-92d5-6d61ed03565d"></a><a name="section-16.9"></a><p></p>
<h2>17.10 Concomitant Medication</h2>
<p class="First">Patients should be advised to inform their physicians if they are taking, or plan to take,    Symbyax . Patients should also be advised to inform their physicians if they are taking, plan to take, or have stopped taking any prescription or over-the-counter drugs, including herbal supplements, since there is a potential for interactions .
                                    <span class="Sup">Â®</span><span class="Italics">[see Â </span><span class="Bold">DRUG INTERACTIONS ( )
                                        <a href="#i4i_interactions_id_59a2af3d-f786-459e-84d4-02bc8ff712f1">7</a></span><span class="Italics">]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_38e7f239-e30b-4472-a8ec-7d945a64383f"></a><a name="section-16.10"></a><p></p>
<h2>17.11 Alcohol</h2>
<p class="First">Patients should be advised to avoid alcohol while taking Olanzapine for Injection .
                                    <span class="Italics">[see Â </span><span class="Bold">DRUG INTERACTIONS ( )
                                        <a href="#i4i_interactions_id_59a2af3d-f786-459e-84d4-02bc8ff712f1">7</a></span><span class="Italics">]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d16f7c18-8711-43c0-81dc-339beb51c65a"></a><a name="section-16.11"></a><p></p>
<h2>17.13 Use in Specific Populations</h2>
<p class="First"><span class="Bold"><span class="Italics">Pregnancy</span></span></p>
<p>Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy with Olanzapine for Injection .
                                    <span class="Italics">[see Â </span><span class="Bold">USE IN SPECIFIC POPULATIONS ( )
                                        <a href="#i4i_pregnancy_id_d0d32cab-bdd8-4428-a965-7fcc395578f7">8.1</a></span><span class="Italics">]</span></p>
<p><span class="Bold"><span class="Italics">Nursing Mothers</span></span></p>
<p>Patients should be advised not to breast-feed an infant if they are taking Olanzapine for Injection .
                                    <span class="Italics">[see Â </span><span class="Bold">USE IN SPECIFIC POPULATIONS ( )
                                        <a href="#i4i_nursing_mothers_id_4707cef8-0542-4f74-b407-6607a781f6f1">8.3</a></span><span class="Italics">]</span></p>
<p><span class="Bold"><span class="Italics">Pediatric Use</span></span></p>
<p>Safety and effectiveness of olanzapine for injection in children and adolescents &lt;18 years of age have not been established.</p>
<p>Symbyax is a registered trademark of Eli Lilly and Company
                                    <span class="Sup">Â®</span></p>
<p>The brands listed are the registered trademarks of their respective owners and are not trademarks of Sandoz Inc.</p>
<p>Manufactured by Gland Pharma Limited</p>
<p>Hyderabad 500043, Andhra Pradesh, India</p>
<p>for Sandoz Inc.</p>
<p>Princeton, NJ 08540</p>
<p>M.L: 103/AP/RR/97/F/R</p>
<p>Revised: October 2011.</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1></h1>
<div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b3bc948-161e-49ee-b67f-4bbb63af23d6&amp;name=64725-3159.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OLANZAPINEÂ 		
					</strong><br><span class="contentTableReg">olanzapine injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64725-3159(NDC:0781-3159)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OLANZAPINE</strong> (OLANZAPINE) </td>
<td class="formItem">OLANZAPINE</td>
<td class="formItem">10Â mg Â inÂ 2Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">50Â mg Â inÂ 2Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TARTARIC ACID</strong></td>
<td class="formItem">3.5Â mg Â inÂ 2Â mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64725-3159-1</td>
<td class="formItem">10 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA201588</td>
<td class="formItem">10/24/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>TYA Pharmaceuticals
							(938389038)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>TYA Pharmaceuticals (938389038)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">TYA Pharmaceuticals</td>
<td class="formItem"></td>
<td class="formItem">938389038</td>
<td class="formItem">RELABEL(64725-3159), REPACK(64725-3159)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5b3c9704-3969-4194-8861-afdf5b27491a</div>
<div>Set id: 3b3bc948-161e-49ee-b67f-4bbb63af23d6</div>
<div>Version: 2</div>
<div>Effective Time: 20111102</div>
</div>
</div>Â <div class="DistributorName">TYA Pharmaceuticals</div></p>
</body></html>
